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Squamous cell carcinoma of the tongue is one of the most prevalent tumors of the head and neck 
region.  The extent of lymph node metastasis is a major determinant for the staging, the most 
reliable adverse factor for prognosis of squamous cell carcinoma of the tongue and it guides 
therapeutic decisions. The Paget‟s “Seed and Soil” theory for cancer and its metastasis is well 
known and established. Angiogenesis and lymphangiogenesis are both important processes 
contributing to tumor progression and metastasis. Cancer research has been driven to understand 
tumor-induced angiogenesis and lymphangiogenesis. Primary tumors can induce lymph channel 
and vasculature reorganizations within sentinel lymph nodes before the arrival of cancer cells. 
The key blood vessels in such lymph nodes that are remodeled are identified as high endothelial 
venules (HEV). The morphological alteration of HEV in the presence of a cancer, coupled with 
the increased proliferation rate of the endothelial cells, results in a functional shifting of HEV 
from immune response mediator to blood-flow carrier. Previous studies have demonstrated the 
role of HEV in inflammatory setting. It was demonstrated that a cancer-induced reorganization is 
quite different from an endotoxin-induced inflammatory alteration. Our preliminary studies of 
HEV and its role in lymph nodes of patients with squamous cell carcinoma of the tongue with 
clinico-pathological correlations revealed a relationship between HEV, cancer metastasis and 
clinical outcome. These pathological processes are reviewed and clinical phenomena explained 
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Table 1  






Table 2 Adverse features of tongue SCC 
 
Adverse features of Tongue Cancer 
1.  Extracapsular nodal spread (ECS) 
2.  Positive margins 
3.  pT3 or pT4 primary 
4.  N2 or N3 nodal disease 
5.  Nodal disease in Levels IV or V 
6.  Perineural invasion 





Table 3: Immunohistochemistry Protocol 
Steps Process Time 
1 Deparaffinization  
2 Antigen Retrieval  20 mins 
3 Rinse with Phosphate Buffered Saline(PBS) briefly 2 mins 
4 Add 3% Hydrogen Peroxide- incubate   15 mins 
5 Wash with PBS 5 mins 
6 Add Horse Serum (blocking serum)- incubate 15 mins 
7 Add Primary antibody (anti-MECA 79), incubate overnight 12 hours 
8 Wash with PBS and put on belly dancer  5 mins 
9 Add Biotinylated secondary antibody 10 mins 
10 Wash with PBS and put on belly dancer  5 mins 
11 Add Streptavidin/peroxidase- incubate  5 mins 
12 Wash with PBST X 2 times  
(5 mins each time) 
10 mins 
13 Wash with Antibody Dilution Buffer (PBE) 3 times  
(3 mins each time) 
9 mins 
14 Add Novo Red- develop for 10 mins 10 mins 
15 Counter stain IHC  
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Summary of the secondary analysis in the supplementary data 
Tumor Characteristics  Clinical data  Relative 
Risk  
p  
Tumor volume (TV)  Overall Survival  0.985 0.476 
 Disease Free Interval  0.990 0.481 
Stage (S) Overall Survival  1.116 0.71  
 Disease Free Interval   1.302 0.348 
Grade(G) Overall Survival 0.882  0.815  
 Disease Free Interval   1.436 0.308 
Since there are no statistical difference noted between the 2 groups, we now consider the 
2 groups (Cases and Controls) as a cohort and repeat the analysis summarized below 
(i.e. without considering the group ) 
Tumor volume (TVc) Overall Survival 0.994 0.765 
 Disease Free Interval 0.994 0.648 
Stage (Sc) Overall Survival 1.364 0.327 
 Disease Free Interval 1.209 0.255 
Grade(Gc) Overall Survival 1.121 0.822 
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Kaplan Meier Overall Survival curves for the two groups (Cases vs. Controls) 
 


















Dilated HEVs with red blood cells in its lumen (high power field) 
 
 






Metamorphosis of HEVs in a tumor microenvironment.  
This process begins with the HEV increasing in absolute numbers, then each of them becoming 
more dilated and lastly every one of them will become a function vessel carrying blood. 
Normal HEVs (A) Dilated HEVs (B) Dilated HEVs with rbcs 
within its lumen (C)
IHC with Meca-79 Antibody in High Power Field 








Overall survival relative risk with respect to the different HEVs ratios  
 
 no. of all HEVs : A 
 no. of dilated HEVs (defined as lumen size more than 80square micron) : B 
 no. of dilated HEVs with red blood cells (rbcs) inside its lumen : C 
 Percentage of dilated HEVs with respect to total no. of HEVs i.e. Ratio of dilated HEVs 
to the total number of HEVs : B/A  
 Percentage of dilated HEVs with rbcs within its lumen with respect to total no. of dilated 
all HEVs i.e. Ratio of dilated HEVs with rbcs within its lumen to total no. of dilated 
HEVs : C/B 
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HEV was remodeled from a thick-walled, endothelial vessel with a small lumen to a thin walled, 
large-lumen vessel 
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Venn diagram illustrating the relationship between the different HEV parameters (A, B, C). 













5. Introduction and Background 
Cancer remains one of the leading causes of morbidity and mortality worldwide. Oral and 
pharyngeal cancers is ranked as the eighth most common cancer diagnosed in men in the United 
States (1) . Despite advances in surgery and radiation therapy, the 5-year survival rate for oral 
cancer has not improved significantly over the past several decades and remains at 50–55% (2, 3) 
. This is primarily because patients continue to die from metastatic disease at regional and distant 
sites as well as from local recurrence. 
 
Cancer research has focused a great deal on the pathogenesis of metastasis as the presence of 
metastases often translate to a grave prognosis with relatively little effective therapeutic 
measures currently available, in contrast to early non-metastatic lesions.  
 
Dissemination of primary malignant cancer cells is traditionally described as being via several 
routes. Firstly, by direct local invasion into the surrounding tissue or transcoelomic spread by 
seeding of the cancer cells into body cavities e.g. peritoneal, pleural surfaces. Secondary, via 
systemic metastasis via tumor-associated blood vessels to distant organs and or, lymphatic 
metastasis via tumor associated lymphatic vessels to draining sentinel lymph nodes (SLN), then 
to distal lymph nodes, and from there to distal organs. Lastly, via transplantation, mechanical 
deposition or spillage of cancer cells by surgery or use of instruments during diagnostic 
procedure e.g. biopsy.   
 
Sentinel lymph node metastasis is the initial step in the spreading of cancer in many 
malignancies. The first lymph node was called the „„sentinel node‟‟ by Cabanas in 1977, 
studying penile cancer, who defined the concept of the sentinel node being the doorway to the 
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regional node basin (4). The modern concept of SLN represents the group of LN in the first 
draining station, this usually represents about 2 to 6 nodes in each echelon. This assumption has 
now been firmly established in breast cancer, melanoma, and other cutaneous sites such as vulvar 
and Merkel cell cancers but is less well defined in others such as thyroid, head and neck, gastric, 
colorectal, cervical, and endometrial cancers. 
 
The sentinel or the regional lymph nodes undergoes morphological and functional changes 
induced by the primary tumor. These are reflected and may be brought into effect by vasculature 
and lymph channel reorganizations even before the arrival of cancer cells. The key blood vessels 
in such lymph nodes that are remodeled are identified as high endothelial venules (HEV) (5) . 
Tumor-reactive lymphadenopathy in SLNs has been observed for decades, but alterations of the 
lymphatic channels and vasculature in these nodes before the arrival of metastatic tumor cells 












6. Squamous Cell Carcinoma of the Tongue 
6a. Epidemiology  
Oral and pharyngeal cancers is ranked as the eighth most common cancer diagnosed in men in 
the United States (1) .  It is estimated that about 35,310 new cases of oral cavity and 
oropharyngeal cancer will be diagnosed in the United States in 2008; 25,310 in men and 10,000 
in women. An estimated 7,590 people (5,210 men and 2,380 women) will die of these cancers in 
2008 (6) . As the incidence of oral cancer continues to increase, the disease becomes an 
increasingly important public health issue. The World Health Organization (WHO) predicts a 
continuing worldwide increase in the number of cases of oral cancer for the next several decades 
(7) . It was indicated that oral cancer in Europe constituted between 25% to 35% of all cancers 
then (7) .  
 
Of all the carcinomas of the head and neck, tongue is the most prevalent site. The results of 
numerous studies suggest that head and neck cancer, particularly oral tongue cancer, is 
increasing in young adults internationally (8-14) . This may be attributed to the higher incidence 
of young people picking up smoking and the increasing incidence of HPV infection in young 
adults. 
 
 In the United States, an increase in the tongue cancer mortality rate in adults younger than 30 
years has been described (12). Oral tongue cancers are also associated with an increased 
proportion of female patients, non-smokers and aged <40 years (15) . It has also been reported 
worldwide to be a raising cause of mortality in males (7) .   
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6b. Clinical and Pathological features 
Oral tongue SCC was associated with poorer survival compared with other oral cavity and head 
and neck sites (11, 12, 16, 17) .  
 
The oral tongue is the oral cavity subsite associated most commonly with squamous cell 
carcinoma (SCC). Previous studies have demonstrated that cancers of the oral tongue are distinct 
biologically and epidemiologically from other tumors of the oral cavity (15) .  
 
There are many risk factors associated with oral cancer including tongue cancer. There are 
commonly known as the 6 “S”, namely, smoking, spirits(alcohol), sex, syphilis, sunlight, 
exposure (lip carcinoma), immunosuppressed states ( AIDS, post-transplant patients). About 
90% of people with oral cavity and oropharyngeal cancers use tobacco, and the risk of 
developing these cancers is related to the duration and the amount of tobacco they smoked or 
chewed.  Tobacco smoke from cigarettes, cigars, or pipes is associated with the increased 
incidence of cancer in general and they arise from anywhere in the oral cavity and oropharynx, 
lungs, esophagus, kidneys, bladder, and several other organs. Oral tobacco products usage is also 
associated with cancers of the oral mucosa and inner surface of the lips.  
 
Alcohol consumption, in addition to smoking strongly increases a person‟s risk of developing 
oral cavity and oropharyngeal cancers. About 70% with oral cancer are heavy alcohol drinkers. 
People who are particularly heavy alcohol drinkers but don't smoke still retain a high risk of 
these cancers, but it is the combination of the alcohol consumption and tobacco usage that is the 




Oral and oropharyngeal cancers are about twice as common in men as in women. This may 
attributed to the common fact that men are more likely to use tobacco and alcohol. This 
difference is decreasing as more women are now using tobacco and drinking nowadays. 
 
Nutritional factors may play a role as well. Several studies have found that a diet low in fruits 
and vegetables is linked with an increased risk of cancers of the oral cavity and oropharynx. This 
may be confounded by the poorer dentition and prevalence of poorer general dental health and 
hygiene in this population of lower social economic status. 
   
Human papilloma viruses (HPV) are a group of more than 100 related viruses. Most HPV types 
and benign and cause viral warts on various parts of the body, but a few HPV types seem to be 
involved in some cancers. Cancer of the cervix is the most notorious cancer to be associated with 
many strains of HPV. The same HPV types (especially HPV strain 16) are found in some oral 
and oropharyngeal cancers (18) . The current view is that HPV may be a factor in the 
development of up to a third of oral and oropharyngeal cancers. People with oral cancer linked 
with HPV infection are less likely to be smokers and drinkers, and in general seem to have a 
better outlook than those without HPV. HPV-positive tumors have a better clinical outcome and 
prognosis.  
 
Immunosuppression is known to be associated with cancer development e.g. people with 
Acquired Immunodeficiency Disease (AIDS) are known to be at risk of developing Kaposi 
sarcoma. Drugs that suppress the immune system to prevent rejection of transplanted organs or 
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to treat certain immune system diseases may be at increased risk for cancers of the oral cavity 
and oropharynx.  
 
Lichen Planus is a skin condition that occurs mainly in middle-aged people. Most often it affects 
the skin, presenting as an itchy rash but it sometimes affects the oral and oropharyngeal muscoa, 
appearing as small white lines or spots. A severe case may slightly increase the risk of oral 
cancer.  
 
There are many other unproven and controversial risk factors reported in the literature. The 
common mouthwash has high alcohol content, it has been suggested to be linked with a higher 
risk of oral and oropharyngeal cancers. Studies researching this possible association are plagued 
by the confounding fact that most smokers and frequent are more likely to use mouthwash than 
people who neither smoke nor drink. It has been suggested that long-term irritation of the oral 





6c. Current Opinions on management and therapy of Squamous Cell Carcinoma of the 
Tongue 
 
The tongue is the most common intraoral site of cancer in most countries. The oral tongue is the 
site in oral cavity associated most commonly with squamous cell carcinoma (SCC). 
 
Clinical Presentation 
Cancer of the tongue may grow to significant size before they cause symptoms. Approximately 
three quarters of the cancer occurs in the mobile tongue and most are well differentiated tumors. 
Tongue cancer may spread easily because the tissue planes separating the intrinsic tongue 
musculature are lax. They often become symptomatic when its size interferes with movement 
causing speech or swallowing problems or when they cause pain. Squamous cell carcinoma of 
the tongue may arise in apparently normal epithelium, in areas of leukoplakia or in an area of 
chronic inflammation e.g. chronic glossitis. These lesions are often larger than 2 cm at 
presentation, with the lateral border being the most common subsite. At an advanced stage, the 
patient may develop speech and swallowing dysfunction. Pain can sometimes occur when the 
tumor involves the lingual nerve and this pain may also be referred to the ear as a result. 
Carcinomas of the tongue base are clinically silent until they deeply infiltrate the tongue 
musculature. They are often less differentiated. As a result of a relative asymptomatic early stage 
combined with the difficulties with direct visualization, they may extend into the oral tongue or 




The evaluation of a patient with tongue cancer begins with a detailed history and a complete 
head and neck clinical examination. History includes specifically asking about tobacco and 
alcohol use and quantifying its usage, pain, weight loss, articulation difficulties, referred otalgia, 
hemoptysis, hoarseness, and dysphagia and odynophagia. During a complete head and neck 
examination, attention is directed at the site and size of the lesion and any infiltrating 
characteristics; a thorough bimanual examination of the tumor, the surrounding floor of mouth, 
and the submandibular triangles is performed. Lymphadenopathy is carefully examined with the 
palpation of the bilateral neck and this is completed with a full dental evaluation, with attention 
to dental hygiene, dentition status, and integrity of the mandible. A sample of the lesion e.g. 
punch biopsy may be obtained in the clinical setting or as part of the endoscopic evaluation of 
the tumor to obtain pre-operative confirmatory histology. If indicated, Examination under 
Anesthesia (EUA) may be helpful especially for posterior or base of tongue cancers (19) .  
 
A comprehensive whole body examination is also performed with attention to assessing the 
fitness for surgery or adjuvant therapy and to exclude metastatic disease.  The clinical evaluation 
is completed with appropriate imaging modalities e.g. Computed Tomography (CT) or Magnetic 
Resonance Imaging (MRI). 
 
Imaging Investigations 
Radiologic evaluation with a CT scan and MRI has revolutionized the assessment of patients 
with head and neck tumors. An MRI has higher soft tissue resolution and the assessment of the 
mobile tongue may be facilitated. Involvement of the extrinsic tongue musculature and direct 
extension in the submandibular glands and the base of tongue can be revealed with MRI. The 
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response to therapy also may be evaluated more thoroughly. As part of the staging and 
management processes, confirmation of nodal disease, vascular distortion or involvement, bony 
destruction, or potential space involvement aids in the diagnosis.  
 
Both CT scan and MRI are generally reliable for detecting the extent of soft tissue and bony 
involvement in persons with oral cavity carcinoma (20) . However, MRI has several well 
established advantages in staging tumors of the oral cavity. The soft tissue contrast between 
tumor and normal musculature is higher on T2-weighed images. With MRI, there is minimum or 
no beam artifact from amalgam or other dental material. Imaging with MR can be performed and 
reconstructed in sagittal, coronal, and axial planes giving the surgeon a 3-Dimension impression 
for a more accurate tumor assessment and this aids in surgical planning. The contrast between 
post-irradiation fibrosis and recurrent tumor is also better appreciated on T2-weighed images. 
 
Recently, with the advent of positron emission tomography (PET), combining PET and CT is a 
new diagnostic and staging modality in the evaluation of the patient with head and neck cancer. 
PET scans are used most often to reveal cancer and to examine the effects of cancer therapy by 
characterizing biochemical changes in the cancer. These scans can be performed on the whole 
body or can be localized to the head and neck. 
 
A PET scan demonstrates the biological changes in the tissues or organs before anatomical 
changes take place by utilizing the radiotracer 18-fluorodeoxyglucose (FDG), while the CT scan 
provides information about the body's anatomy, such as size, shape, and location. Squamous cell 
carcinomas and many other malignant tumors demonstrate increased glucose metabolism as 
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compared to normal tissues. [18F]-fluoro-2-deoxy-D-glucose is a glucose analogue that may be 
delivered intravenously and preferentially transported into squamous cell carcinomas by glucose 
transporters By combining these 2 scanning technologies, a PET-CT scan enables physicians to 
more accurately diagnose and identify cancer and its extent. These can be used as a tool in the 
initial evaluation of the patient who presents for initial staging, as well as for evaluating response 
to treatment and detection of recurrences (21) . The major disadvantage of PET scan currently 




There are no established biochemical tumor markers for tongue cancer. The incidence of distant 
metastases at initial presentation is low and therefore the only laboratory workup needed is 
directed at the evaluation of the patients' underlying medical conditions and assessing the 
patient‟s fitness for surgery. A full blood cell count and a biochemical panel of urea, creatinine 
and electrolytes is a useful general screening tool A Chest X-ray (CXR) and 12-lead 
Electrocardiogram (ECG) are standard pre-operative investigations for any person undergoing 
major surgery, general anesthesia or aged above 40 years old. Usually for patients undergoing 
major surgery or in patients with a history or suspected bleeding diathesis, investigations may 
also include tests of prothrombin time (PT), partial thromboplastin time (PTT), and international 
normalized ratio (INR). These tests will help the primary physician to establish if further testing 






The treatment approach is best managed by a multi-disciplinary team. The role of clinical 
evaluation with history taking, physical examination and imaging is to help guide treatment 
options by staging the cancer using the American Joint Committee on Cancer (AJCC) TNM 
Staging System (22) . (Table 1)  
 
Early lesions (T1 and T2) of the tongue may be managed by surgery or by radiation therapy (RT) 
alone. Both modalities produce 70% to 85% cure rates in early lesions. Moderate excisions of 
tongue, even hemiglossectomy, can often result in surprisingly little speech disability provided 
the wound closure is fashioned such that the tongue is not bound down. If, however, the 
resection is more extensive, problems may include aspiration of liquids and solids and difficulty 
in swallowing in addition to speech difficulties. Occasionally, patients with tumor of the tongue 
require almost total glossectomy. Larger lesions generally require combined surgical and 
radiation treatment. The control rates for larger lesions are about 30% to 40%. More advanced 
lesions may require segmental bone resection, hemi-mandibulectomy, or maxillectomy, 
depending on the extent of the lesion and its location. 
 
Generally, surgery if possible is the preferred main stay of treatment and offers the best option if 
there are no contraindications. Treatment with surgery alone for early or superficial lesions or in 
combination with adjuvant radiotherapy for more advanced lesions is the standard of care. For 
tongue cancers and all SCC of the head and neck, the neck needs to be considered as part of the 
treatment. The cervical nodes can be treated with either surgery, radiation therapy or both. Major 
advances have been made in surgical approaches, reconstructive options, and the rehabilitation of 
patients who have oral cavity and tongue SCC. These advances have significantly improved 
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disease-specific outcome and quality of life. The therapeutic decision must take into 
consideration the patient's age, lifestyle, and willingness to participate in the therapeutic regimen. 
The treatments have substantially different morbidities and may result in significant differences 
in quality of life.  
 
The treatment protocol according to the Stage is detailed below and summarized in Figure 3. The 
treatment guidelines according to the internationally well- accepted National Comprehensive 
Cancer Network (NCCN) recommendations are classified into several groups: 
1. T1 or T2, N0 
2. T3, N0 
3. T1 to T3, N1 to N3;  T4a, any N 
4. Unresectable. 
 
1. Treatment guidelines for T1 or T2, N0 tumors 
The preferred option is excision of the primary tumor with or without a unilateral or 
bilateral selective neck dissection. The decision of whether a neck dissection is done 
depends on clinical suspicion and judgment on the risk of occult cervical LN metastasis. 
Generally, if the risk deemed to higher than 20%, most institutions would elect a form of 
neck dissection. Bilateral neck dissections are performed based on clinical judgment and 
if the lesion is central or near the midline. Recently intra-arterial chemotherapy combined 
with radiotherapy has been shown to have good organ preservation and reasonable 




After surgery, the treatment is stratified according to the presence or absence of adverse 
features. (Table 2) If there are no adverse features noted, no adjuvant therapy is needed. 
If there is one positive LN without adverse features, RT is an option to be considered. If 
adverse features of ECS and/or positive margins, Chemo/RT   is recommended. If there 
are any other risk factors present, RT alone or Chemo/RT are the options. 
 
The other option of primary treatment is External-beam RT with or without 
brachytherapy. If there is evidence of residual disease, salvage surgery is recommended. 
 
2. Treatment guidelines for T3, N0 tumors 
The guideline is excision of the primary tumor and reconstruction as indicated and a 
unilateral or bilateral selective neck dissection. If there are no adverse features noted, RT 
is optional. If adverse features of ECS and/or positive margins, Chemo/RT is 
recommended. If there are any other risk factors present, RT alone or Chemo/RT are the 
options. 
 
3. Treatment guidelines for T1 to T3, N1 to N3 tumors; T4a, any N tumors 
Surgery is the mainstay of treatment. In this group of patients, choice of surgery is 
dependent on the nodal status.  
 
For N0, N1, N2a, N2b, N3 tumors, the recommendation is excision of the primary tumor 
and an ipsilateral comprehensive with or without a contralateral selective neck dissection 




For N2c (i.e. bilateral or contralateral LNs metastasis) tumors, the recommendation is 
excision of the primary tumor and a bilateral comprehensive and reconstruction as 
indicated. 
 
Adjuvant therapy recommendation is the same, i.e. If there are no adverse features noted, 
RT is optional. If adverse features of ECS and/or positive margins, Chemo/RT is 
recommended. If there are any other risk factors present, RT alone or Chemo/RT are the 
options. 
 
4. Treatment guidelines for unresectable tumors 
Any newly diagnosed unresectable; T4b; N+ unresectable tumors, the standard treatment 
options are: 
a. Concurrent Cisplatin or Carboplatin-based chemotherapy + RT (Category 1 
evidence) (Figure 2) 
b. Clinical Trial if available 
c. Definitive RT plus concurrent systemic chemotherapy. (Category 3 evidence) 
d. Induction chemotherapy followed with chemoRT. (Category 3 evidence) 
e. Induction chemotherapy followed with RT. (Category 3 evidence) 
f. Definitive RT. (Category 2a evidence) 





Systemic Therapy and Radiotherapy 
 
Systemic Therapy and Radiotherapy are reserved for advanced HNSCC. The treatment of 
locoregionally advanced squamous cell carcinoma of the head and neck has evolved gradually 
from surgery as the mainstay of treatment to radiotherapy as the principal treatment. Additional 
benefit has been obtained with hyperfractionated radiotherapy and with radiotherapy combined 
with chemotherapy (chemoradiotherapy). The value of chemoradiotherapy is, however, 
counterbalanced by increased and often prohibitive toxicity, particularly among patients with 
coexisting medical conditions and decreased performance status.  
 
A multinational, randomized study in 2006 by Bonner et al. studied Radiotherapy alone versus 
Radiotherapy plus cetuximab (Erbitux, ImClone Systems), an IgG1 monoclonal antibody against 
epidermal growth factor receptor (EGFR), in the treatment of loco-regionally advanced 
squamous -cell carcinoma of the head and neck. The addition of cetuximab to high-dose 
radiotherapy significantly increased both the duration of control of locoregional disease and 
survival among patients with locoregional advanced head and neck cancer. These benefits were 
achieved without the prohibitive in-field toxic effects often associated with high- dose 
radiotherapy to the head and neck (23) .  
 
The principles and details of Systemic Therapy and Radiotherapy according to the NCCN are 






Patients with treated tongue or oral cavity cancers are followed up on periodic physical 
examination, 1 to 3 monthly in the first year; 2 to 4 monthly in the second year; 4 to 6 monthly in 
year 3 to year 5 and after 5 years, 6 months to yearly. During the follow-ups, chest imaging as 
clinically indicated. Speech, hearing and swallowing evaluation and rehabilitation as indicated. 
Smoking cessation and dental followed is also recommended. 
 
 
6c i.  Role of Neck Dissection in the surgical management of tongue cancer 
The head and neck encompasses perhaps some of the most anatomically complicated regions of 
the body. Good knowledge of the lymphatic system is essential to understand the pattern of 
spread of cancer in the neck. About a third of all the lymph nodes in the body are in the head and 
neck region. Most squamous cell carcinomas of the head and neck are at least potentially curable 
if the neck is appropriately treated as well, as the risk of occult metastasis in tongue cancer can 
be up to 20% to 40%. Metastasis to cervical lymph nodes occurs more frequently from the 
tongue than from any other primary tumor site in the oral cavity. 
 
The LNs in the cervical region are described by levels that correspond to their anatomic location. 
(I-VII). The LNs in the submental and submandibular triangles make up level I, and the upper, 
middle, and lower jugular nodal groups are considered levels II, III, and IV, respectively. The 
posterior triangle of the neck is designated as level V, while the pre-laryngeal, pre-tracheal, and 
para-tracheal nodes comprise level VI. Level VII includes the lymph node groups found in the 




The tongue has a dense lymphatic network, with three main deep muscular lymphatic drainage 
pathways. The anterior pathway drains the tip of the oral tongue, primarily to level I or level II. 
The lateral pathway drains the lateral 1/3 of the dorsum of the tongue to levels I, II, III. The 
central pathway drains the central 2/3 of the tongue. These vessels drain to the level I nodes or 
course through a sublingual node and terminate in the level III nodes. Most of the lymph from 
the oral tongue drains to levels I and II.  The levels most frequently involved with single 
pathologic lymph node metastasis in SCCOT are levels I, II, and III  (24) .  
 
The prognostic value and significance of metastatic disease in the cervical lymph nodes of head 
and neck cancer has long been appreciated and well established in many studies. Since the 19th 
century, surgeons have attempted to remove involved cervical lymph nodes at the time of 
resection of the primary cancer, a systematic approach to en bloc removal of cervical lymph 
nodes. Radical en bloc Neck Dissection has been described by a Polish surgeon, Jawdyn´ski in 
1888 and subsequently popularized by American Surgeon Dr. George W. Crile in the 1906. Dr. 
George W. Crile of Cleveland, Ohio has since been regarded in North America as the 
“Forefather” of head and neck cancer surgery, akin to what Dr. William Stewart Halsted is to 
breast surgery. These pioneers‟ work provided the basis of our current techniques. Washington 
University in 1933 described their experience in 131 cases and advocated the removal of the 
spinal accessory nerve during neck dissection as it facilitated a more complete removal of the 
cervical lymph nodes and shortens operative time (25) . Over the next few decades, 
developments included preservation of the spinal accessory nerve in selected cases, elective neck 
dissection performed in association with resection of various primary tumors, bilateral neck 
dissection and limited neck dissection were reported and practiced with varying results. In 1963, 
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the first description of an effective technique of modified radical neck dissection was published 
in Spanish by Sua´rez, in 1963. His technique preserves three important structures, the internal 
jugular vein, sternocleidomastoid muscle and spinal accessory nerve, this technique was further 
refined and modified by various authors who published their results in the English language 
literature during the period from 1964 through 1990 and beyond. Modified or „„functional‟‟ neck 
dissection gains popularity because the technique avoids much of the morbidity of radical neck 
dissection while achieving equivalent degrees of control of regional disease in properly selected 
cases. By the late 20th century, the concept of selective neck dissection, consisting of resection 
of only the nodal groups at greatest risk for metastasis from a given primary site, was studied and 
developed.  
 
Due to various techniques and the lack of standardization, in 1988, the Committee for Head and 
Neck Surgery and Oncology of the American Academy of Otolaryngology-Head and Neck 
surgery (AAO-HNS) convened a committee to standardize the nomenclature. This is updated 
recently and confirmed by the Committee for Neck Dissection Classification,
 
American Head 
and Neck Society; representation from the Committee
 
for Head and Neck Surgery and Oncology, 
American Academy of
 
Otolaryngology–Head and Neck Surgery (T.A.D.) (26) .  They defined 
the following nomenclature for neck dissections (ND). 
 
1. Radical ND, considered to be the standard procedure for cervical lymphadenopathy  
2. Modified radical ND, this encompasses any alteration of the radical procedure that 
involves preservation of one or more non-lymphatic structures of the neck. 
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3. Selective ND, this terms includes supraomohyoid (SOHND), posterolateral, lateral and 
anterior NDs, each representing a specific procedure that preserves one or more lymph 
node groups routinely removed in radical neck dissection. 
4. Extended ND, or any alteration involving removal of additional lymph node groups or 
non-lymphatic structures relative to the radical procedure 
 
Newer or other nomenclature in the literature includes comprehensive neck dissection, it is one 
that removes all the LN groups as one would in a radical neck dissection, whether the internal 
jugular vein, sternocleidomastoid muscle and spinal accessory nerve are preserved does not 
affect whether the dissection is comprehensive or not. Similar to MRND, Functional ND, 
describes removing the entire lymphatic system of the neck by dissecting the fasciae surrounding 
the non- lymphatic structures, thus preserving the sternocleidomastoid, internal jugular vein, and 
accessory spinal nerve.  
 
Prospective studies have demonstrated similar rates of neck recurrence and survival after elective 
selective neck dissection compared to elective modified radical neck dissection. Other 
modifications and factors applied to treatment of cervical lymph node disease include the use of 
adjuvant and neo-adjuvant radiation and chemotherapy, the identification of various adverse 
prognostic factors such as extracapsular spread and extranodal soft tissue deposits, application of 
sentinel lymph node biopsy to staging of the neck, the use of immunohistochemical and 
molecular techniques for identification of lymph node metastases not detectable by light 





6c ii. Role of Sentinel Lymph Node Biopsy in Oral Tongue Cancers 
 
The sentinel lymph node biopsy (SLNB) derives from a concept pioneered more than 40 years 
ago (28) . In 1977, Cabanas studying penile carcinoma, using the experience from a hundred 
cases, he defined the concept of the sentinel node being the doorway to the regional node basin 
(4) . Since then, with this assumption and belief that the SLN‟s histological status is 
representative of its LN basin, the procedure has been gaining momentum and greater interest 
from the scientific community. Breast cancer and melanoma are the two pathological states in 
which the SLNB has been most established and validated and thus widely used. 
 
Sentinel lymph node biopsy (SLNB) is a minimally invasive technique that allows the surgeon to 
excise the primary draining lymph nodes, in order for the pathologist to examine and determine 
the presence of subclinical metastases with the aid of frozen sections histopathology intra-
operatively. The procedure is performed with the assistance of radio-labelled dye injection and/ 
or lymphoscintigraphy. This technique offers a less invasive technique to stage the lymphatic 
basins of a patient with a primary malignancy and allows detailed examination of the first 
echelon lymph node basin for metastases. Sentinel lymph node biopsy techniques have also 
evolved and improved with time and technological advances, recently some papers has shown 
the usefulness and potential of Single Photon Emission Computed Tomography and Computed 





Sentinel lymph node biopsy is currently used in many studies on a trial and experimental status 
for validation in many cancers e.g.  colorectal, gastric , cervical carcinomas. In tongue cancers 
and head and neck squamous cell carcinoma (HNSCC), the pathologic status of the regional 
lymph nodes remains the most important disease prognosticator. Head and neck squamous cell 
carcinoma is often considered a loco-regional disease and the incidence of distant metastasis is 
relatively low, whereas the incidence of occult loco-regional disease i.e. occult metastasis in 
cervical LNs even in early stage Tongue SCC can be up to 20% to 30% (31) . This is in contrast 
to cancers such as melanoma or breast cancer in which lymph node staging is a more accepted 
indicator of distant metastasis.  In the past before the age of CT and MRI, clinical examination 
has been the mainstay for determining the presence of LN metastasis. Naturally because of the 
inconsistency and unreliability of palpation alone and with the invention of CT and MRI, 
physicians have utilized these imaging modalities to detect the presence of nodal metastasis. 
However, even now, the current imaging tests have been shown to be not reliable in the detection 
of early nodal disease.  
 
Sentinel lymph node biopsy is currently used as a staging procedure in HNSCC at some 
European centers and is under active investigation in the United States in an ongoing American 
College of Surgeons Oncology Group (ACOSOG) trial (32, 33) .   
 
In a multicentre prospective trial, Ross et al. reported their preliminary results. They performed 
227 SNB procedures, 93% of the time, a sentinel node was identified. Of 59 positive nodes, 57 
were identified with the intra-operative gamma probe and 44 with blue dye. They upstaged 
patient‟s diseases in 34%. The sensitivity of the technique was 93%. The identification of SLNB 
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for floor of mouth (FOM) tumours was 86%, compared with 97% for other tumours. The 
sensitivity for FOM tumours was 80%, compared with for other tumor groups. They concluded 
that SLNB can be successfully applied to early tumours of the oral cavity and oropharynx in a 
standardized fashion by centres worldwide and for the majority of these tumours this technique 
can be used alone as a staging tool (33) . 
 
Rigual et al. reported in a small prospective study looking at oral carcinoma and the role of 
SLNB. They identified SLNs in all their patients (100%) and accurately predicted the pathologic 
nodal status in 90 % of their patients (90%). Occult nodal metastases were present in 60% of the 
cohort. They reported sensitivity and specificity of SLNB in their patient population of 83% and 
100%, respectively, with that they conclude that SLNB is technically feasible and accurate but 
they also mentioned that sentinel node biopsy can be more technically demanding in the head 
and neck region especially tumours at the FOM, than in other anatomical sites due to the 
proximity of the tumour and especially Level I LNs (34) .  
 
There are challenges unique to SLNB in HNSCC including tongue cancers. It is a 
multidisciplinary technique and like all new techniques requires a learning curve and this is made 
more difficult as it requires all three stages, the preoperative lymphoscintigraphy, the intra-
operative identification of the cervical SLN and the pathological assessment of the SLN, to be 
proficient before any results can be accurately assessed. 
 
From the surgical view point, most cervical LNs are small even if they contain metastasis. 
Studies have shown that approximately 33% to 58% of occult metastases are smaller than 3 mm 
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and in 25% of patients, LNs smaller 3 mm were the only metastatic nodes detected in the neck. 
Intra-operative identification of these small nodes is a technique challenge, especially when the 
SLN is located within a group of nodes or embedded in fat tissue, in the complex anatomical 
region of the head and neck. This is complicated by the fact that lymphatic drainage patterns 
from head and neck sites are not as predictable as those observed in the extremities and multiple 
SLNs in multiple LN basins are common in SCC of the head and neck. 
 
Factors in failures of SLNB were discussed by Hornstra et al. It is noted that patients with a 
negative pre-operative lymphoscintigraphy were found more likely to have an unsuccessful SNB 
procedure and notably, anterior tongue tumours or FOM tumours were also found to have a 
higher likelihood of SLNB failure due to a „„shine through‟‟ phenomenon. This occurs due to the 
proximity of the sentinel node to the injection site.  Patients with clinically palpable LNs or 
advanced primary tumors are independent factors associated with an unsuccessful SLNB. The 
presence of nodal involvement may lead to distortion of the normal lymphatic architecture by the 
tumour, blocking the normal drainage to the SLN and forcing an alternative drainage pathway, 
leading to inaccurate identification of the sentinel node or to complete failure of identification.  
Sentinel lymph node biopsy (SLNB) has become an accepted diagnostic tool for determining 
whether metastasis are present in the first echelon of draining lymph nodes in melanoma and 
breast cancer patients. Sentinel lymph node biopsy has allowed these patients to avoid surgical 
morbidity while being accurately upstaged for their malignancies. The role of SLNB in the 
management of HNSCC patients is currently undefined and in the process of systematic 
validation. If this technique could be successfully applied to HNSCC, it would represent a 




6d. Controversies and issues regarding treatment options in Squamous Cell Carcinoma of 
Tongue 
 
Treatment of squamous cell carcinoma of the tongue generally follows the same regime as any 
SCC of the Head and Neck. The biologically aggressive characteristic of oral SCC is well 
characterized by its ability to metastasize to cervical lymph nodes. The 5-year survival rate can 
decrease below 20% when cervical metastasis is present (36) . In management of SCC of the 
tongue, it is essential to note that in addition to the treatment of the primary tongue lesion, 
management of the involved cervical LNs also represents an important component of the 
therapeutic strategy. In the 1970s and still practiced in some parts of the world, the treatment 
regimen for oral SCC patients was to use a “wait-and-watch” policy for negative neck and to 
perform a form of ND only for a positive neck. After implementing the wait-and-watch policy, it 
was observed that some patients later presented with advanced unresectable lesions in the neck. 
Elective neck dissection (END) was accepted and incorporated into the treatment regime for 
clinically “negative” neck (cN0). Despite the advent of new imaging modalities like CT, MRI 
and recently PET-CT, due to the lack of any other precise non-invasive methods to predict 
cervical metastasis, elective neck dissection is still the recommended approach to patients with 
clinically negative neck (cN0) when the probability of occult metastasis is estimated to be in 
excess of 20% (37) .  
 
Debate regarding the efficacy of END existed for more than four decades. The surgical technique 
of neck dissections has evolved from radical neck dissection (RND) to modified or functional 
neck dissection and then to selective neck dissection (SND). Selective neck dissection appears to 
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be effective as a staging procedure for cases with no clinical evidence of cervical nodal disease 
(cN0) and possibly also for cases with microscopic disease. Although this notion proposes an 
interesting possibility, until recently it is only supported by the results of retrospective studies 
including highly selected groups of patients. The purpose of SND is to selectively remove the 
lymphatic groups at the highest risk for metastasis and to decrease morbidity by preserving the 3 
crucial structures namely, the sternocleidomastoid muscle, internal jugular vein, and the spinal 
accessory nerve, which is routinely dissected in RND. 
 
As discussed earlier in the section under the role of neck dissection in HNSCC, radical neck 
dissection seemed to be unacceptable for patients with negative neck because of the poor quality 
of life due to the morbidities associated with it, such as shoulder disability, neck pain and long-
term adverse disfiguring cosmetic effects. Recently, improved experience from longer follow-up 
data synergized with better knowledge of defined lymphatic drainage patterns in oral SCC 
prompted many head and neck surgeons to consider SND as the standard approach to clinically 
negative neck (cN0)  (38) . The main advantage of SND is that it removes only the Level I, II 
and II LNs (the nodes at the greatest risk for metastasis) to decrease morbidity and post-operative 
dysfunction while the oncologic outcome remains unchanged. Review of the literature suggests 
that SND can provide valuable pathologic information for staging and further adjuvant treatment. 
However, the effectiveness of SND, especially compared with RND, has been controversial. 
Many published literature regarding the efficacy of supraomyohyoid neck dissection (SOHND) 




A major prospective trial by the Brazilian Head and Neck Cancer Study Group looked at the role 
of SOHND versus modified RND in the management of oral SCC (37) . In this study, all LNs 
suspected of metastasis in the SOHND group were submitted to frozen section, and the 
operations were converted to modified RND when neck nodes were found to be positive. The 
occult metastatic rate recurrence rates in the SOHND group were not significantly different from 
the RND group, therefore they conclude that SOHND seems to be as effective as RND in 
providing valuable staging information for patients with oral SCC and negative neck. For 
patients with nodal disease, postoperative radiotherapy did not significantly decrease recurrence 
rate in either the SOHND or RND groups. This suggests that such recurrences were related more 
to the aggressive biologic characteristics of oral SCC than the operative technique. In patients 
with nodal disease, consistent with other literature, SOHND alone in patients with positive neck 
was inadequate therapy for regional control without post-operative radiotherapy. The Brazilian 
Head and Neck Cancer Study Group concluded that the recurrence and survival rates were 
similar in both groups and SOHND can be recommended as standard elective treatment for 
patients with T2–T4 oral squamous cell carcinomas. 
 
More recently, the questions are pertaining to the need to remove level IV LNs as skip metastasis 
is a known phenomenon (39) .  The benefit for extension of SOHND to level IV nodes has been 
controversial so far. Current literature advocates routinely extending SOHND to level IV nodes 
in patients with SCC of the tongue and floor of the mouth because the procedure does not 
significantly increase operating time and adds little morbidity to the operation (40) . This study 
suggests that after careful examination of suspected level III lymph nodes by frozen section, 
extension to level IV nodes would be justified if they are found to be positive (41) .  
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7. Pathogenesis of a lymph node metastasis 
Tumor cell metastasis to regional lymph nodes often marks the first step in tumor cell 
progression. The presence of metastatic cells in regional lymph nodes is the most important 
prognostic factor for malignant tumors of epithelial origin and along with extracapsular spread 
(ECS) of the cervical lymph nodes, they are the most important prognostic factors in patients 
with squamous cell carcinoma (SCC) of the tongue (24, 42-44) . In general, carcinomas 
metastasize through the lymphatic system more often than sarcomas, this may be explained by 
the fact that sarcomas expresses low levels of lymphatic stimulators and due to the presence of 
endogenous lymphangiogenic inhibitors. The lymphatic metastatic cascade is a series of complex 
interrelated steps and processes. It starts as the tumor grows and enlarges; cytokines are secreted 
to promote lymphangiogenesis. New lymphatics may grow, some within the tumor, but in the 
majority of carcinomas, they propagate towards the tumor (45) . As malignant cells invade the 
extracellular matrix, they enter the lymphatics lumen. They can move singly or in clusters to the 
sentinel or the first echelon of regional lymph nodes. This subset of tumor cells invades the 
cortex of the lymph node and proliferates and metastasizes to other lymph nodes. Traditionally 
viewed as a passive process, it has been suggested, but remains undetermined that the passage of 
tumors cells through the lymphatic channels is guided by mechanical forces. The interstitial fluid 
and hydrostatic pressure differential forces the cells and fluid towards the peri-tumor lymphatics 
(46) ; it is also guided by expression of adhesion receptors and the mechanism of chemokinesis 
(47) . Both processes are probably important and necessary. As the tumor grows, the interstitium 
swells and opens the intercellular clefts, facilitating the passage of fluid and cells into the 
lymphatic drainage away from the tumor with retrograde flow prevented by valves. These 
structural properties such as the lack of basement membrane in terminal lymphatics,  presence of 
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the intercellular clefts. In addition, the traumatic serum environment in the blood stream, which 
are often toxic to the tumor cells, may account for the observation that in many solid tumors, 
lymphatic metastasis precedes metastasis via the vascular system.  
 
 
Angiogenesis and lymphangiogenesis 
Mammals possess two vascular systems, the blood vasculature and the lymphatic systems.  
The lymphatic system consist of lymphoid organs such as the thymus, lymph nodes, the bone 
marrow, the spleen and specialized cells e.g. Peyer‟s patches connected by conduits called 
lymphatic vessels that are lined by single layer of lymphatic endothelial cells. The lymphatic 
conducting system carries the lymph and consists of tubular vessels that include the lymph 
capillaries, the lymph vessels, and the right and left thoracic ducts. The blood does not directly 
come in contact with the parenchymal cells and tissues in the body, but constituents of the blood 
first exit the microvascular exchange vessels to become interstitial fluid, which comes into 
contact with the parenchymal cells. Lymph is formed when interstitial fluid enters the initial 
lymphatic vessels of the lymphatic system. The lymph is then moved along the lymphatic vessel 
network by either intrinsic contractions of the lymphatic vessels or by extrinsic compression of 
the lymphatic vessels via external tissue forces e.g. the contractions of skeletal muscles. 
 
The lymphatic system has several interrelated functions. It is responsible for the removal of 
interstitial fluid from tissues; it absorbs and transports fatty acids and fats as chyle to the 
circulatory system; it transports immune cells to and from the lymph nodes into tissues and 
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marrow. The lymph transports antigen-presenting cells (APCs), such as dendritic cells, to the 
lymph nodes where an immune response is stimulated. The lymph also carries lymphocytes from 
the efferent lymphatics exiting the lymph nodes. Lymphangiogenesis is the development and 
proliferation of new lymphatics from host vessels.  
 
Blood vasculature consist of blood endothelial cells, basal membrane, smooth muscles cells and 
pericytes organizing into capillaries, venules, veins , arterioles and arteries in a circular manner, 
driven by the heart. It is the main system for transport of oxygen, carbon dioxide, nutrients, 
metabolic waste products, hormones and cells of the immune system and many factors around 
the body.  
 
Angiogenesis is the generation of endothelial cells from existing blood vessels. If a cancerous 
tumor is larger than 1–2 mm in size, then angiogenesis is needed to prevent tumor cell apoptosis. 
Both systems, though distinctly different, have been shown with little doubt to be both 
functionally and morphologically related in many aspects. Tumor angiogenesis can occur in 
many ways and involve many complex processes and regulatory factors e.g. anti-angiogenic, 
pro-angiogenic factors. These include sprouting angiogenesis, intussusceptive angiogenesis, 
vasculogenesis, vasculogenic mimicry and vessel co-option to name a few (48). Many of the 
factors involved in this complex interplay include members of Vascular endothelial growth 
factor (VEGF) family, which is first identified in 1989. The VEGF family of growth factors now 
consists of six members (VEGF-A, VEGF-B, VEGF-C, VEGF-D, VEGF-E and placental growth 
factor), they are general activators of endothelial cell proliferation and mobility. As a group, it is 
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the most potent factor that increases permeability of the vessel wall, induces vasodilatation of the 
existing vessels, it increases the expression of matrix metalloproteinases and plasminogen 
activators for the degradation of the extracellular matrix and subsequently endothelial cell 
migration.  
 
It is of no surprise and logical that the relationship between angiogenesis and lymphangiogenesis 
is extensively studied recently especially in cancer research. This is most pertinent in the biology 
of lymph node metastasis where the two systems literally lie side by side. There is now extensive 
direct evidence showing members of the VEGF family, namely VEGF-C,VEGF-D and recently 
VEGF-A  (49), are not only important regulators of lymph vessel growth in vivo but also 
enhance lymphatic metastasis  (45, 50-52) .  
 
This is significant because there is now evidence that tumor can activate both lymph node 
lymphangiogenesis and angiogenesis before they metastasize which translates into logical efforts 
in largely neglected field of anti-cancer research targeting pathways of tumor 
lymphangiogenesis.   In fact, there are encouraging results from therapeutic targeting of the 
VEGF receptor 3(VEGFR-3) pathway, which is the main activating pathway of which VEGF-C, 
VEGF-D are its ligands. Endostatin, 20-kDa C-terminal fragment of collagen XVIII, which is 
associated with down regulation of VEGF-A and VEGF-D, inhibited growth and lymph node 
metastasis of Squamous cell carcinoma (SCC) in xenograft models and demonstrated reduced 
lymphatic and vascular density (53) . Antibody to VEGF-D inhibits lymphangiogenesis and LN 
metastasis in a VEGF-D-dependent mouse tumor model (50) . A combination of both anti-
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VEGFR-2 and VDGFR-3 blocking antibodies was shown to be more efficient in murine 
xenograft models to reduce overall tumor burden in the lymph nodes and distant metastases, than 
each alone (54) .  
 
More than 25 anti-angiogenic drugs are in clinical trials. The first anti-angiogenic agent, 
bevacizumab (Avastin
TM
), a monoclonal antibody to VEGF-A, was approved by FDA in 2004. It 
has proven clinical benefits in treatment of metastatic colorectal cancer when the drug was added 
to standard chemotherapy and also has recent positive results in metastatic breast cancer and lung 
cancer. There are more than 30 ongoing trials including Phase III clinical trials in advanced or 






Other molecular pathways that harbor potential targets which have varying degrees of anti-
angiogenesis and anti-lymphangiogenesis are ligands such as hepatocyte growth factor (HGF), 
receptors like Neuropilin 2, PDGFRα/β and others such as Angiostatin, interferon α/β and 
platelet-factor 4 (56) . Two other antiangiogenic drugs, Sorafenib (Nexavar
TM
, Bayer) and 
Sunitinib (Sutent
TM
, Pfizer), have also been approved by the FDA. They target multiple receptor 
tyrosine kinases, including VEGF receptors and platelet-derived growth factor (PDGF) receptors 
(57) . Sorafenib and Sunitinib have been beneficial in the treatment of metastatic renal-cell 
cancer when used alone (58, 59) .  Sorafenib monotherapy is also active in the liver and was 




8. High endothelial venules (HEV) and its role 
 
8a. Morphological Features and Functions 
Lymph nodes are central to the pathogenesis of metastasis and the concept of sentinel LNs as the 
first lymphatic basin has been studied extensively in the latter half of the twentieth century. The 
concept that the pathological status of this special group of LNs is representative of the rest of 
the lymphatic basin and distant organs is now established in melanoma and carcinoma of the 
breast and benefited patients significantly as it has decreased surgical morbidity.  If the first 
echelon group of lymph nodes is where the action lies, then the sentinel node is the gateway to 
this party. Blood vessels and lymphatic vessels maintain homeostasis in lymph nodes. High 
endothelial venules are specialized post-capillary venules found in lymphoid tissues, located 
mainly in the T-call zones such as the para-cortical areas of LNs. They are distinct from ordinary 
venules, morphologically and functionally, and besides the vascular endothelial cells (ECs) of 
the blood-brain barrier, the ECs of HEV are the next most well studied. Each HEV has a 
prominent peri-vascular sheath; a thick basal lamina and the layer of ECs are tall and plump in 
appearance. (Illustration 2) There are adhesion molecules common to all venules e.g. CD31, 
Intercellular adhesion molecule 2(ICAM-2), some particular molecules e.g. glycosylated and 
sulphated forms of sialomucins (also known as peripheral node addressins, PNADs), 
glycosylation-dependent cell-adhesion molecule 1(GLYCAM1), CD34, endomucin, podocalyxin 
and enodglycan. There are some lymphoid chemokines e.g. Chemokine ligand 19(CCL19), 





8b. High endothelial venules and its markers 
High endothelial venules are characterized and studied extensively in the field of immunology. 
The evidence suggests that HEV has a central role in lymphocyte trafficking to LNs, allows the 
entrance of native L-selectin 
high
 cells in to the LN parenchyma and this is in large part mediated 
by chemokines produced in and around HEV such as the PNADs. There is a synchrony between 
HEV and lymphatic vessels revealed by immunization studies. LNs undergo remodeling with 
complex kinetics of lymph flow, cell content flow, blood flow, HEV gene expression and its 
morphological changes (60) .  
 
8c. High endothelial venules‟ role in immunology and cancer 
Recently, with animal models, it was shown that before the arrival of metastasis in the SLN, 
there are reorganizations of vasculature and lymphatic channels resulting in the SLN to become a 
functional blood vessel enriched organ. These prominent blood vessels are remodeled HEV. The 
extent of lymph sinus dilation correlated with the primary tumor weight and this is consistent 
with findings from other studies that, in contrast to angiogenesis, where flow only occurs after 
development of vessels, lymphangiogenesis can be induced by interstitial fluid channeling. The 
analogous role of HEV in immune function and cancer metastasis ends here. In inflammatory 
conditions, HEV‟s chief role in the traffic control of lymphocytes can be evident from the 
presence of lymphocytes in the dilated lymphatic sinuses; whereas in tumor-reactive 
lymphadenopathy, there are few cells, suggesting different processes, in which may be due to a 
change of HEV‟ role. There are also studies in murine models to suggest that the movement of 
tumor cells to LNs resembles the normal migration of dendritic cells during immune stimulation, 
resulting in the term “Tumor cell trafficking” (61) . This observation coupled with the 
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knowledge of the intimate relationship between HEV and lymphatic vessels in LNs leads to the 
logical hypothesis that HEV might provide the shortcut or a bypass route connecting the vascular 
and lymphatic system at the level of the SLN.  This is in contrast to the Halstedian philosophy 
that an enbloc resection of the primary cancer and its regional lymphatic basin will achieve cure 
as its assumption is that tumor cells follow a stepwise pathway, from the primary tumor to the 
regional lymph nodes and to the next echelon and then to the systematic circulation through 
distal lymphaticovenous connections such as the thoracic duct. We know that this orderly fashion 
is not all true as from clinical follow-up studies, about 20% of women with node-negative breast 
cancer go on to develop distant metastases (62) .  This is consistent with the analysis of sentinel 
lymphadenectomies suggesting that 20% of systemic metastases are derived from cancer cells 
that bypass this orderly lymphatic route (63) . The HEV providing the vehicle of this shortcut 
route for the cancer cells, might account for a subset of these patients. 
 
In addition to this hypothetical role of providing the physical shortcut route in the LNs, the HEV 
evident from the presence of red blood cells within and significant increase size of the lumen in 
the presence of a tumor, hints that it presumably functions like a blood vessel in anticipation to 
supply the needs for an accelerating growth of a soon-to-arrive tumor deposit. This may explain 
in part that the tumor in nodes are frequently larger and faster growing than the primary itself 
like in the cases of nasopharyngeal carcinomas. This phenomenon is also consistent with the 
better chemotherapy and or radiotherapy responses in metastatic lesions of the breast and head 
and neck cancers, in part due to the lower proportion of hypoxic cancers cells and the increased 




Remodeled HEV in the LN is shown to be capable of being further integrated into tumor 
vasculature after the secondary tumor nest is established in the LN (5, 64). This is the process of 
vessel co-option and this form or tumor angiogenesis is reported as an important component of 




9. Aim and Hypothesis of the Study 
Specific aim: 
We aim to confirm the morphological and functional alterations of high endothelial venules 
(HEVs) in the regional lymph nodes of the patients with carcinomas of the tongue and correlate 
these findings with clinical outcome.  
 
Hypothesis: 
Primary tongue cancer can induce vascular rearrangement in regional lymph node before 
metastasis to facilitate the growth of secondary cancer in the lymph node, resulting shorter 
patients‟ survival.  The key blood vessels involved are high endothelial venules, with its function 
shifting from immune response to blood flow carrier. This transformation of HEV in the 
presence of cancer is a spectrum and these morphological features of altered HEV will correlate 
with clinical outcome of patients, establishing its pivotal role in the pathogenesis of metastasis. 
This association will serve high endothelial venules as a novel prognostic marker and a potential 
candidate for therapeutic targeting.   
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10. Patients, Materials and Methods 
 
10a. Patients  
This study is based on 175 consecutive patients with squamous cell carcinoma of the head and 
neck who have undergone primary surgical treatment at the Head and Neck Unit of the 
Department of General Surgery, Singapore General Hospital and the Department of Surgical 
Oncology, National Cancer Center, Singapore, from January 2001 through to December 2005. A 
retrospective review of these patients‟ pathological and clinical data including follow-up 
information was obtained from the Department of General Surgery Head and Neck database. For 
the purpose for this study, our inclusion criteria includes all surgically treated patients with 
histologically proven SCC tongue with any form of neck dissection and with a minimum of 2-
year follow up period. Exculsion criteria includes all patients with non-SCC tongue cancers, 
patients with non-tongue SCC cancers of the Head and Neck, patients with any previously 
radiated or treated necks, patients with a second primary cancer and patients without a minimum 
of a 2 year follow up period, patients without surgery and/or a neck dissection as part of their 
primary treament.  
 
All patients included had radical excision of the primary tongue lesion and a neck dissection 
according to our departmental protocol. In both of the cases and control group, all had radical 
enbloc excision of the primary tongue lesion with or without resection of adjacent structures with 
either a unilateral or a bilateral, supraomohyoid neck dissection or a modified radical neck 
dissection. Tumours were classified according to the AJCC TNM Staging Classification (22) , 
based on a pre-operative clinical evaulation and this determined the type of neck dissection 
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performed by the primary surgeon. Intra-operative frozen sections were performed for margins 
of the tongue lesion and further resection of the tongue was performed in event that the surgical 
margins were invovled.  
 
Upon discharge from the hospital, they were followed up at regular intervals of monthly, 3-
monthly, 6-monthly and yearly at a progessive rate according to individual surgeon‟s preference. 
Inpatient and outpatient clincal data, pathological, radiological and operative records were 
retrieved from a central medical records office and from the department of pathology. These 
information are retrospectively reviewed and entered into our departmental head and neck 




We conducted a retrospective review and analysis of the  primary SCC tongue lesion and their 
respective lymph node tissues in the neck dissection specimen from the 65 cases of tongue 
cancer patients who had undergone radical surgery with sufficient clinical follow-up information.  
The lymph node tissues in each case are separated into 5 levels according to their anatomical 
locations.   
 
Patient suitability and  selection will be  based on our inclusion and exclusion criteria. The tumor 
and the neck dissection paraffin tissue blocks from the selected patients are retrieved from the 




An independent head and neck pathologist( SK Hwang) reviewed the histological specimens and 
selected the 3 largest lymph node in both groups for staining of the HEV. The largest 3 lymph 
nodes were chosen as it is shown that size of a lymph node correlates with the degree of tumor 
lymphadenopathy and in the cases of the non-metastatic neck, the degree of reactive 
lymphadenopathy. 
 
Optimisation of the immunohistochemical staining protocol and subsequent staining of the HEV 
using the MECA-79 antibody ,which is specific for HEV, was performed. (Table 3) 
 
 
10c. Computer assisted Image Analysis 
 
This was carried out in collaboration with the researchers at Van Andel Research Institute 
(VARI, Grand Rapids Michigan, U.S.A) and our institution. The digital capture of the HEV 
images and the quantitative image analyses are performed at Van Andel Research Institute 
(VARI) using the slide scanner(ScanScope, Aperio T3; ScanScope Console v. 9.0. Aperio 
Technologies, Vista, CA  U.S.A) utilising an illuminator(Fiber-Lite DC-950, Dolan Jenner, 
Boxborough, MA, U.S.A). 
 
We analyzed 3, 5 or 10 snapshots of largest 3 lymph nodes of 10x magnification, depending on 
the size of the LN. The total number of HEV, abnormal HEV, defined as having a lumen area of 
80 square microns, and the HEV with presence of red blood cells were counted with the aid of 
imaging software (J image with cell counter plug-in) An average value for each of these 
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parameter were taken for every LN. These 3 values were co-related to the size of its respective 
LN and the patient‟s clinical data, namely, the overall survival, disease free interval and 
recurrence rate. 
 
Definitions of the HEVs’s parameters and ratios 
This is represented by the following alphabets A, B and C for  the ease of discussion in the rest 
of the results and discussion sections. 
 no. of all HEV : A 
 no. of dilated HEV (defined as lumen size more than 80square micron) : B 
 no. of dilated HEV with red blood cells (rbcs) inside its lumen : C 
 
10d. Statistical Analysis 
 
Correlating with the clinical information from our prospective Head and Neck Cancer database, 
we analyzed the 3 parameters (A, B, C) and the 3 ratios (B/A, C/B, C/A) with respect to several 
clinical parameters, namely Disease Free Interval (DFI) and overall survival in the 2 groups( 
Cases vs. Controls) and as a whole cohort as well. We used Cox‟s Proportional Hazard Model 
for analysis. 
 
For non-parametric data analysis, a non-parametric tests, e.g.  Wilcoxon-rank-sum test and 
Kruskal-Wallis test, were performed in appropriate situations. E.g. to test the difference on 





There are 76 patients with histologically proven squamous cell carcinoma of the tongue and their 
histology were reviewed. This group of 76 patients are stratified according the presence or 
absence of pathologically proven lymph node metastases. Out of this SCC tongue group of 76 
patients, 65 patients were included and 11 patients was excluded because of either the 
unavailability of the their tissue paraffin blocks and/or the lack of sufficient clinical and follow-
up data. 
 
The patients in the group with primary SCC tongue and absence of pathologically proven lymph 
node metastases in their neck dissection specimen are designated as “cases” and patients in the 
other group with primary SCC tongue and presence of pathologically proven lymph node 
metastases in the neck dissection specimens, they are designated as “controls”.  
 
As detailed in the Material and Method‟s section, we performed image analysis looking at the 
number of HEVs, the number of dilated HEVs (defined as lumen size more than 80 square 
micron) and lastly no. of dilated HEV with red blood cells inside its lumen in the 3 largest LN of 
each patient and achieved an average number for each patient based on a HPF (10 X 10) 
magnification field. This is represented by the following alphabets A, B and C for the ease of 
discussion in the rest of the results and discussion sections. (Illustration 3) 
 no. of all HEVs : A 
 no. of dilated HEVs (defined as lumen size more than 80square micron) : B 
 no. of dilated HEVs with red blood cells (rbcs) inside its lumen : C 
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 In addition to these three parameters, we also analyzed the ratios of these abnormal HEVs (B 
and C) with respect to the total number of HEVs (A). This is summarized below as  
 Percentage of dilated HEVs with respect to total no. of HEVs i.e. Ratio of dilated HEVs 
to the total number of HEVs : B/A  
 Percentage of dilated HEVs with rbcs within its lumen with respect to total no. of dilated 
all HEVs i.e. Ratio of dilated HEVs with rbcs within its lumen to total no. of dilated 
HEVs : C/B 
 Percentage of dilated HEVs with rbcs within its lumen with respect to total no. HEVs : 
C/A 
10a. Summary of  Results 
Disease Free Interval analysis 
The sample data suggested a statistically significant association of number of HEVs (A) to the 
disease free interval (DFI). This is statistically significant when controlling for the group (control 
vs. case) (p-value = 0.022). There is also statistical significance when we combined both group 
as one cohort (control + case) (p-value = 0.023). The sample data did not detect any significance 
in DFI between controls and cases (p-value = 0.472). (Table 4 Summary of results) 
 
Overall survival analysis 
The sample data suggested marginal significance in terms of overall survival time between 
controls and cases (p-value = 0.066). (Figure 8)  There was no significance detected found in the 
total no. of  HEVs (A); no. of dilated HEVs (B); no. of dilated HEVs with rbcs inside its 











10b. Main Results in Detail 
We analyzed the clinical parameters of Disease Free Interval (DFI) and overall survival (OS) of 
the patients with respective to their groups (Cases versus Controls). The patients with no lymph 
node metastases in the neck dissection specimen are designated as CASES and patients with 
positive lymph node metastases are designated as CONTROLS. This is analyzed in an effort to 
establish or exclude whether the presence of metastasis in the regional cervical LNs is a factor in 
the HEV reorganization. 
 
Statistical Analysis: 
1.) Fit the „disease free interval (DFI)‟ and „overall survival (OS)‟for two groups of patients 
















   or  )exp()()( 110 xttj    
Where )(0 t is the baseline hazard. 
A total of 65 patients with 30 controls and 35 cases were included in the analysis to estimate the 








1.A) Overall Survival: 
Variables in the Equation 
 B SE Wald df Sig. Exp(B) 95.0% CI for Exp(B) 
 Lower Upper 
Group -1.475 .802 3.383 1 .066 .229 .048 1.102 
 
 
We compared the overall survival between cases and controls and analyzed the relative risk [exp 
(B)] in the above output. The risk of case group is estimated to be 0.229 times of the risk of 
control group based on the study sample (a 95% C.I. is 0.048 ~ 1.102). (Figure 8) 
 
In another words, the risk of control group is 367.4
229.0
1   times higher. This equates that the 
patients with presence of metastases in their regional cervical LNs have a 4.367 higher chance of 
dying as compared to patients without metastasis in their regional LNs. This is marginally 











Kaplan Meier Overall Survival curves for the two groups (Cases vs. Controls) 
 












1.B) Disease free interval: 
Similarly, we compared the disease free interval between control and case and looked at the 
relative risk [exp (B)] in the above output. The risk of case group is estimated to be 0.75 times of 
the risk of control group based on the sample (a 95% C.I. is 0.342 ~ 1.644). This implies that in 
patients without LN metastases, if recurrences occur, the DFI tend to be longer. However, this 
did not achieve is not statistical significance (p-value = 0.472) (Figure 9) 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 
Lower Upper 









2.) In the second part, we analyzed the DFI and OS for the 2 groups (cases vs. controls) with 
respect to the 3 HEVs parameters (A, B, C)  
 Total no. of  HEVs : A 
 no. of dilated HEVs (defined as lumen size more than 80 square micron) : B 
 no. of dilated HEVs with red blood cells (rbcs) inside its lumen : C 
Fit the „disease free interval (DFI)‟ and „overall survival (OS)‟ for the two groups (control  











X   and   2X be the values of HEV or Dilated HEV or RBC 





   or  )exp()()( 22110 xxttj    
Where )(0 t is the baseline hazard. 
 
2.A) Analysis of Overall Survival and HEVs parameters (A, B, C)  
a). Association of A (total no. of HEV) and OS– 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 Lower Upper 
Group -.848 .630 1.813 1 .178 .428 .125 1.472 
HEV(A) .023 .032 .520 1 .471 1.024 .961 1.091 




To observe the association of A (total no. of HEV) on overall survival while controlling for the 
group (control vs. case), we looked at the relative risk [exp(B) – in purple circle] in the above 
output. While controlling for the group, the risk is estimated to be 1.024 times when the HEV 
value increase by 1 based on the sample (a 95% C.I. is 0.961 ~ 1.091). However, the association 
of A (total no. of HEV) and overall survival is not significant while controlling for group (p-
value = 0.955) 
To further illustrate the meaning of the above output, we write up the hazard functions under 
certain group and HEV values: 
)002.0477.1exp()()( 210 xxttj    
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Control & HEV = 0 0 0 1.00 
Control & HEV = 1 0 1 1.024 
Control & HEV = 2 0 2 
2
)024.1(  
Case & HEV = 0 1 0 0.428 
Case & HEV = 1 1 1 024.1428.0   
Case & HEV = 2 1 2 
2








b). Association of B („no. of dilated HEV‟) and OS – 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 
Lower Upper 
Group -.904 .651 1.932 1 .165 .405 .113 1.449 
Dilated 
HEVs(B) 
.069 .097 .507 1 .476 1.071 .886 1.295 
 
To observe the association of B („no. of dilated HEV‟) on overall survival while controlling for 
the group (control vs. case), we can look at the relative risk (exp(B) – in purple circle) in the 
above output. While controlling for the group, the risk is estimated to be 1.071 times when the 
dilated HEV value increase by 1 based on the sample (a 95% C.I. is 0.886 ~ 1.295). However, 
the association of B („no. of dilated HEV‟) and overall survival is not statistically significant 
while controlling for group (p-value = 0.476) 
To further illustrate the meaning of the above output, we write up the hazard functions under 
certain group and B („no. of dilated HEV‟) values: 
 















Control & B = 0 0 0 1.00 
Control & B = 1 0 1 1.071 
Control & B = 2 0 2 2)071.1(  
Case & B = 0 1 0 0.405 
Case & B = 1 1 1 071.1405.0   
Case & B = 2 1 2 
2
)071.1(405.0   
 
 
c). Association of C („HEV with red blood cells within its lumen‟) and OS– 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 
Lower Upper 
Group -.851 .632 1.813 1 .178 .427 .124 1.474 
HEV with 
rbcs (C) 
.110 .116 .893 1 .345 1.116 .889 1.401 
 
To observe the association of C („HEV with red blood cells within its lumen‟) on overall survival 
while controlling for the group (control vs. case), we can look at the relative risk [exp(B) – in 
purple circle] in the above output. While controlling for the group, the risk is estimated to be 
1.116 times when the RBCs in HEV value increase by 1 based on the sample (a 95% C.I. is 
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0.889 ~ 1.401)). However, the association of C („HEV with red blood cells within its lumen‟)  
and overall survival is not statically significant while controlling for group (p-value = 0.345) 
 
2.B) Analysis of Disease Free Interval and HEVs parameters (A, B, C) 
a). Association of the A (total no. of HEV)  and DFI 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 
Lower Upper 
Group -.312 .401 .604 1 .437 .732 .334 1.607 
HEV (A) .050 .022 5.215 1 .022 1.051 1.007 1.097 
 
To observe the association of HEV on disease free interval while controlling for the group 
(control vs. case), we looked at the relative risk (exp(B) – in purple circle) in the above output. 
While controlling for the group, the risk is estimated to be 1.051 times when the HEV value 
increase by 1 based on the sample (a 95% C.I. is 1.007 ~ 1.097).  
 
The association of A (total no. of HEV) and disease free interval is significant while controlling 









b). Association of the number of B („no. of dilated HEV‟) and DFI– 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 
Lower Upper 
Group -.319 .407 .616 1 .432 .727 .327 1.613 
Dilated HEVs (B) .033 .063 .284 1 .594 1.034 .915 1.169 
 
To observe the association of B („no. of dilated HEV‟) on disease free interval while controlling 
for the group (control vs. case), we looked at the relative risk (exp(B) – in purple circle) in the 
above output. While controlling for the group, the risk is estimated to be 1.034 times when the 
dilated HEV value increase by 1 based on the sample (a 95% C.I. is 0.915 ~ 1.169). However, 
the association on B („no. of dilated HEV‟) and disease free interval is not significant while 
controlling for group (p-value = 0.594) 
 
c). Association of C („HEV with red blood cells within its lumen‟) and DFI – 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 
Lower Upper 
Group -.291 .401 .527 1 .468 .748 .341 1.640 
HEV with rbcs 
(C) 
.043 .078 .300 1 .584 1.044 .896 1.216 
 
To observe the association of C („HEV with red blood cells within its lumen‟) on disease free 
interval while controlling for the group (control vs. case), we looked at the relative risk [exp(B) – 
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in purple circle] in the above output. While controlling for the group, the risk is estimated to be 
1.044 times when the RBCs in HEV value increase by 1 based on the sample (a 95% C.I. is 
0.896 ~ 1.216). However, the association on C („HEV with red blood cells within its lumen‟) and 













3.)  In the third part of our analysis, we further analyzed the DFI and OS for the 2 groups  
(cases vs. controls) with respect to the 3 ratios of HEVs parameters, as detailed below.  
  Ratio of dilated HEVs to the total number of HEVs : B/A  
 Ratio of dilated HEVs with rbcs within its lumen with respect to total no. HEVs : C/A 
 Ratio of dilated HEVs with rbcs within its lumen to total no. of dilated HEVs : C/B 
We fit the „disease free interval (DFI)‟ and „overall survival (OS)‟ for the two groups (control vs. 
case) with ratios of HEV and Dilated HEV and RBC values 
 Let  
case
control







X  and   2X be the ratio values of B/A or C/A or C/B 
Then the hazard function of an individual j, )(tj , with certain 1X  and 2X  values can be 




   or  )exp()()( 22110 xxttj    
Where )(0 t is the baseline hazard. 
 
3.A) Overall Survival and HEV ratios 
a) Association of the „ Ratio of dilated HEVs to the total number of HEVs(B/A)‟  and Overall 
Survival  
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 
Lower Upper 




To observe the association of B/A („Ratio of dilated HEVs to the total number of HEVs‟) on 
overall survival, we can look at the relative risk, exp(B), in the above output. The risk is 
estimated to be 1.078 times when the ratio value increase by 1 based on the sample. However, 
the association of B/A („Ratio of dilated HEVs to the total number of HEVs‟) and overall 
survival is not significant (p-value = 0.982). 
 
b) Association of the C/A („Ratio of dilated HEVs with rbcs within its lumen with respect to 
total no. HEVs‟) and Overall Survival  
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 
Lower Upper 
C/A 1.288 3.833 .113 1 .737 3.624 .002 6634.427 
 
To observe the association of C/A („Ratio of dilated HEVs with rbcs within its lumen with 
respect to total no. HEVs‟) on overall survival, we can look at the relative risk, exp(B) in the 
above output. The risk is estimated to be 3.624 times when the ratio value increase by 1 based on 
the sample. However, the association of C/A („Ratio of dilated HEVs with rbcs within its lumen 







c) Association of the C/B („Ratio of dilated HEVs with rbcs within its lumen to total no. of 
dilated HEVs‟)and Overall Survival 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 
Lower Upper 
C/B 2.884 2.108 1.871 1 .171 17.884 .287 1114.678 
 
To observe the association of the C/B („Ratio of dilated HEVs with rbcs within its lumen to total 
no. of dilated HEVs‟) on overall survival, we can look at the relative risk, exp(B) in the above 
output. The risk is estimated to be 17.884 times when the ratio value increase by 1 based on the 
sample. However, the association of C/B („Ratio of dilated HEVs with rbcs within its lumen to 
total no. of dilated HEVs‟) and overall survival is not significant (p-value = 0.171). 
 
3.B) Disease Free Interval and HEV ratios: 
a) Association of the B/A („Ratio of dilated HEVs to the total number of HEVs‟) and Disease 
Free Interval 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 
Lower Upper 
Group -.263 .401 .430 1 .512 .769 .351 1.687 
B/A -2.314 3.061 .571 1 .450 .099 .000 39.890 
 
To observe the association of B/A („Ratio of dilated HEVs to the total number of HEVs‟) on 
disease free interval while controlling for the group (control vs. case), we can look at the relative 
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risk, exp(B), in the above output. While controlling for the group, the risk is estimated to be 
0.099 times when the ratio value increase by 1 based on the sample. In another word, the risk 
will be about 10 times ( 1.10
099.0
1  ) higher when the ratio decreases by 1. However, the 
association of B/A („Ratio of dilated HEVs to the total number of HEVs‟) and disease free 
interval is not significant while controlling for the group (p-value = 0.450). 
 
b) Association of the C/A („Ratio of dilated HEVs with rbcs within its lumen with respect to 
total no. HEVs‟) and Disease Free Interval 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 
Lower Upper 
Group -.287 .401 .513 1 .474 .751 .342 1.645 
C/A -1.541 3.328 .214 1 .643 .214 .000 145.830 
 
To observe the association of C/A („Ratio of dilated HEVs with rbcs within its lumen with 
respect to total no. HEVs‟) on disease free interval while controlling for the group (control vs. 
case), we can look at the relative risk, exp(B),in the above output. While controlling for the 
group, the risk is estimated to be 0.214 times when the ratio value increase by 1 based on the 
sample. In another words, the risk will be about 4.67 times ( 67.4
214.0
1  ) higher when ration 
decrease by 1. However, the association of C/A („Ratio of dilated HEVs with rbcs within its 
lumen with respect to total no. HEVs‟) and disease free interval is not significant while 




c) Association of the C/B („Ratio of dilated HEVs with rbcs within its lumen to total no. of 
dilated HEVs”) and Disease Free Interval 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 
Lower Upper 
Group -.150 .416 .129 1 .719 .861 .381 1.947 
C/B 1.697 1.348 1.585 1 .208 5.458 .389 76.616 
 
To observe the association of the C/B („Ratio of dilated HEVs with rbcs within its lumen to total 
no. of dilated HEVs‟) on disease free interval while controlling for the group (control vs. case), 
we can look at the relative risk, exp(B), in the above output. While controlling for the group, the 
risk is estimated to be 5.458 times when the ratio value increase by 1 based on the sample. 
However, the association of C/B („Ratio of dilated HEVs with rbcs within its lumen to total no. 
of dilated HEVs‟) and disease free interval is not significant while controlling for the group (p-






4.) In the fourth part, we analyzed the DFI and OS with respect to the 3 HEVs parameters (A, B, 
C) and the 3 Ratios  B/A; C/A ; C/B without consider the groups. In another words, we 
analysed all the patients as a single cohort. We fit the „disease free interval (DFI)‟ and „overall 
survival (OS)‟ with the HEVs parameters or the ratios without considering the group.  
Let  
1X be the values of A or B or C or B/A or C/A or C/B 




   or  )exp()()( 110 xttj    
Where )(0 t is the baseline hazard. 
 
4.A) Overall Survival and HEV parameters as a cohort (i.e. without group effect) 
a) Association of Total no. of HEVs (A)  and OS( as a Cohort) 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 





-.003 .035 .006 1 .941 .997 .932 1.067 
 
To observe the association of A (total no. of HEV) on overall survival, we can look at the 
relative risk, exp(B), in the above output. The risk is estimated to be 0.997 times when the HEV 
value increase by 1 based on the sample (a 95% C.I. is 0.932 ~ 1.067). However, the association 





b) Association of  B („no. of dilated HEV‟) and OS ( as a Cohort)  
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 






.004 .111 .001 1 .972 1.004 .808 1.247 
 
To observe the association of B („no. of dilated HEV‟) on overall survival, we can look at the 
relative risk, exp(B), in the above output. The risk is estimated to be 1.004 times when the 
dilated HEV value increase by 1 based on the sample (a 95% C.I. is 0.808 ~ 1.247). However, 
the association of B („no. of dilated HEV‟) and overall survival is not significant (p-value = 
0.972) 
 
c) Association of  HEVs with red blood cells  within its lumen (C) and OS (as a Cohort) 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 






.008 .135 .003 1 .954 1.008 .774 1.313 
 
To observe the association of C („HEV with red blood cells within its lumen‟) on overall 
survival, we can look at the relative risk, exp(B), in the above output. The risk is estimated to be 
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1.008 times when the C („HEV with red blood cells within its lumen‟) increase by 1 based on the 
sample (a 95% C.I. is 0.774 ~ 1.313). However, the association of C („HEV with red blood cells 
within its lumen‟) and overall survival is not significant (p-value = 0.954) 
 
d) Association of the B/A („Ratio of dilated HEVs to the total number of HEVs‟) and Overall 
Survival(as a Cohort) 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 
Lower Upper 
B/A .168 3.656 .002 1 .963 1.183 .001 1532.264 
 
To observe the association of B/A („Ratio of dilated HEVs to the total number of HEVs‟) on 
overall survival, we can look at the relative risk, exp(B), in the above output. The risk is 
estimated to be 1.183 times when the ratio value increase by 1 based on the sample. However, 
the association of B/A („Ratio of dilated HEVs to the total number of HEVs‟) and overall 
survival is not significant (p-value = 0.963). 
 
e) Association of the C/A („Ratio of dilated HEVs with rbcs within its lumen with respect to total 
no. HEVs‟) and Overall Survival (as a Cohort) 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 
Lower Upper 
C/A .160 4.923 .001 1 .974 1.174 .000 18189.501 
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To observe the association of C/A („Ratio of dilated HEVs with rbcs within its lumen with 
respect to total no. HEVs‟) on overall survival, we can look at the relative risk, exp(B) in the 
above output. The risk is estimated to be 1.174 times when the ratio value increase by 1 based on 
the sample. However, the association of C/A („Ratio of dilated HEVs with rbcs within its lumen 
with respect to total no. HEVs‟ )and overall survival is not significant (p-value = 0.974). 
 
f) Association of the C/B („Ratio of dilated HEVs with rbcs within its lumen to total no. of 
dilated HEVs‟) and Overall Survival (as a Cohort) 
 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 
Lower Upper 
C/B .954 1.997 .228 1 .633 2.597 .052 130.178 
 
To observe the association of C/B („Ratio of dilated HEVs with rbcs within its lumen to total no. 
of dilated HEVs‟) on overall survival, we can look at the relative risk, exp(B) in the above 
output. The risk is estimated to be 2.597 times when the ratio value increase by 1 based on the 
sample. However, the association of C/B („Ratio of dilated HEVs with rbcs within its lumen to 







4.B) ) Disease Free Interval and HEV parameters as a cohort (i.e. without group effect) 
Disease Free Interval: 
a). Association of Total no. of HEVs (A)  and Disease Free Interval (as a Cohort) 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 





.049 .022 5.189 1 .023 1.051 1.007 1.096 
 
To observe the association of A (total no. of HEV) on disease free interval, we can look at the 
relative risk (exp(B) – in purple circle) in the above output. The risk is estimated to be 1.051 
times when the A (total no. of HEV) value increase by 1 based on the sample (a 95% C.I. is 
1.007 ~ 1.096). The association of A (total no. of HEV) and disease free interval is significant 
(p-value = 0.023*). 
 
b) Association of  Dilated HEVs (B) and DFI ( as a Cohort) 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 
Lower Upper 
Dilated HEVs(B) .025 .060 .175 1 .676 1.026 .911 1.154 
 
To observe the association of B („no. of dilated HEV‟) on disease free interval, we can look at 
the relative risk, exp(B), in the above output. The risk is estimated to be 1.026 times when the 
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dilated HEV value increase by 1 based on the sample (a 95% C.I. is 0.911 ~ 1.154). However, 
the association of  B („no. of dilated HEV‟) and disease free is not significant (p-value = 0.676) 
 
c) Association of  C („HEV with red blood cells within its lumen‟) and DFI (as a Cohort) 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 
Lower Upper 
RBCsinHEV .041 .076 .289 1 .591 1.042 .897 1.210 
 
To observe the association C („HEV with red blood cells within its lumen‟) on disease free 
interval, we can look at the relative risk, exp(B), in the above output. The risk is estimated to be 
1.042 times when the C („HEV with red blood cells within its lumen‟) value increase by 1 based 
on the sample (a 95% C.I. is 0.897 ~ 1.21). However, the association of C („HEV with red blood 
cells within its lumen‟) and disease free is not significant (p-value = 0.591) 
 
d) Association of the B/A („Ratio of dilated HEVs to the total number of HEVs‟) and DFI (as a 
Cohort) 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 
Lower Upper 




To observe the association of B/A („Ratio of dilated HEVs to the total number of HEVs‟) on 
disease free interval, we can look at the relative risk, exp(B), in the above output. The risk is 
estimated to be 0.095 times when the ratio value increase by 1 based on the sample. In another 
word, the risk will be about 10.5 times ( 5.10
095.0
1  ) higher when ration decrease by 1. 
However, the association of B/A („Ratio of dilated HEVs to the total number of HEVs‟) and 
disease free interval is not significant (p-value = 0.427). 
 
e) Association of the C/A („Ratio of dilated HEVs with rbcs within its lumen with respect to total 
no. HEVs‟) and DFI (as a Cohort) 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 
Lower Upper 
C/A -1.491 3.202 .217 1 .641 .225 .000 119.632 
 
To observe the association of C/A („Ratio of dilated HEVs with rbcs within its lumen with 
respect to total no. HEVs‟) on disease free interval, we can look at the relative risk, exp(B) in the 
above output. The risk is estimated to be 0.225 times when the ratio value increase by 1 based on 
the sample. In another word, the risk will be about 4.44 times ( 44.4
225.0
1  ) higher when 
ration decrease by 1. However, the association of the C/A („Ratio of dilated HEVs with rbcs 
within its lumen with respect to total no. HEVs‟) and disease free interval is not significant (p-




f). Association of the C/B („Ratio of dilated HEVs with rbcs within its lumen to total no. of 
dilated HEVs‟) and DFI (as a Cohort) 
 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 
Lower Upper 
C/B 1.831 1.306 1.966 1 .161 6.243 .482 80.789 
 
To observe the association C/B („Ratio of dilated HEVs with rbcs within its lumen to total no. of 
dilated HEVs‟) on disease free interval, we can look at the relative risk, exp(B), in the above 
output. The risk is estimated to be 6.243 times when the ratio value increase by 1 based on the 
sample. . However, the association of the C/B („Ratio of dilated HEVs with rbcs within its lumen 





11c. Supplementary Data Analysis Results 
In this final section, utilizing information from our prospective data collection, we further 
analyzed our tumor pathological data with respect to the primary tumor volume, the stage of the 
disease and grade of the tumor against the patient‟s overall survival and disease free interval.  
In addition, we also looked into the relationship of the HEV parameters and the 3 ratios 
previously defined and analyzed them against the tumor pathological characteristics, namely the 
primary tumor volume, the stage of the disease and grade of the tumor. 
 
Summary of the secondary analysis (Table 5) 
Tumor Characteristics  Clinical data  Relative 
Risk  
p  
Tumor volume (TV)  Overall Survival  0.985 0.476 
 Disease Free Interval  0.990 0.481 
Stage (S) Overall Survival  1.116 0.71  
 Disease Free Interval   1.302 0.348 
Grade(G) Overall Survival 0.882  0.815  
 Disease Free Interval   1.436 0.308 
Since there are no statistical difference noted between the 2 groups, we now consider the 2 groups                                
(Cases and Controls) as a cohort and repeat the analysis summarized below (i.e. without considering the group ) 
Tumor volume (TVc) Overall Survival 0.994 0.765 
 Disease Free Interval 0.994 0.648 
Stage (Sc) Overall Survival 1.364 0.237 
 Disease Free Interval 1.209 0.255 
Grade(Gc) Overall Survival 1.121 0.822 
 Disease Free Interval 1.493 0.221 
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Supplementary Analysis in detail 
Using Cox‟s Proportional Hazard Model for Overall Survival / Disease Free Interval 
(Tumor volume, stage, grade)  
1.) Fit the „overall survival (OS)‟ or „disease free interval (DFI)‟ for the two groups (control 












X   and   2X be the values of tumor or stage or grade 
Then the hazard function of an individual j, )(tj , with certain 1X  and 2X  values can be 




   or  )exp()()( 22110 xxttj    
Where )(0 t is the baseline hazard. 
 
1.A) Overall Survival: 
a). Tumor volume – 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 Lower Upper 
group -.955 .649 2.163 1 .141 .385 .108 1.374 
Tumor 
volume 
-.015 .022 .508 1 .476 .985 .944 1.027 
 
To observe the association of tumor volume on overall survival while controlling for the group 
(control vs. case), we can look at the relative risk (exp(B) – in purple circle) in the above output. 
While controlling for the group, the risk is estimated to be 0.985 times when the tumor volume 
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increase by 1 unit based on the sample. However, the association of Tumor volume (TV) and 
overall survival is not significant while controlling for group (p-value = 0.476). 
Please note that, in both control and case groups, the tumor volumes among the events (death) 
relatively small comparing to that among the non-death. 
b). Stage (S) – 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 Lower Upper 
group -.607 .993 .374 1 .541 .545 .078 3.817 
Stage .109 .412 .071 1 .790 1.116 .498 2.501 
 
To observe the association of „stage‟ on overall survival while controlling for the group (control 
vs. case), we can look at the relative risk (exp(B) – in purple circle) in the above output. While 
controlling for the group, the risk is estimated to be 1.116 times when the advance to next stage 
based on the sample (a 95% C.I. is 0.498 ~ 2.501). However, the association on stage and overall 
survival is not significant while controlling for group (p-value = 0.79) 
 
c). Grade (G) – 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 Lower Upper 
group -.862 .663 1.692 1 .193 .422 .115 1.548 




To observe the association of „grade‟ on overall survival while controlling for the group (control 
vs. case), we can look at the relative risk (exp(B) – in purple circle) in the above output. While 
controlling for the group, the risk is estimated to be 0.882 times when advance to next grade 
based on the sample (a 95% C.I. is 0.309 ~ 2.521). However, the association on grade and 
overall survival is not significant while controlling for group (p-value = 0.815) 
 
1.B) Disease Free Interval (DFI): 
a). Tumor(TV)– 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 Lower Upper 
group -.383 .418 .839 1 .360 .682 .301 1.547 
tumor_V -.010 .014 .496 1 .481 .990 .963 1.018 
 
To observe the association of tumor volume on disease free interval while controlling for the 
group (control vs. case), we can look at the relative risk (exp(B) – in purple circle) in the above 
output. While controlling for the group, the risk is estimated to be 0.990 times when the tumor 
volume increase by 1 unit based on the sample. However, the association on HEV and disease 
free interval is not significant while controlling for group (p-value = 0.481). 
b). Stage (S)  – 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 Lower Upper 
group .222 .672 .109 1 .741 1.249 .335 4.656 
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Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 Lower Upper 
group .222 .672 .109 1 .741 1.249 .335 4.656 
stage .264 .282 .880 1 .348 1.302 .750 2.261 
 
To observe the association of „stage‟ on disease free interval while controlling for the group 
(control vs. case), we can look at the relative risk (exp(B) – in purple circle) in the above output. 
While controlling for the group, the risk is estimated to be 1.302 times when the advance to next 
stage based on the sample (a 95% C.I. is 0.750 ~ 2.261). However, the association on stage and 
disease free interval is not significant while controlling for group (p-value = 0.348) 
 
c). Grade  – 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 Lower Upper 
group -.120 .436 .075 1 .784 .887 .377 2.085 
Grade(G) .362 .355 1.038 1 .308 1.436 .716 2.881 
 
To observe the association of „grade‟ on disease free interval while controlling for the group 
(control vs. case), we can look at the relative risk (exp(B) – in purple circle) in the above output. 
While controlling for the group, the risk is estimated to be 1.436 times when advance to next 
grade based on the sample (a 95% C.I. is 0.716 ~ 2.881). However, the association on grade and 
disease free interval is not significant while controlling for group (p-value = 0.308) 
74 
 
2.)  Fit the „overall survival (OS)‟ or „disease free interval (DFI) with tumor volume (or 
stage, or grade) without considering the group (since there is no significance found on the 
risk between two groups, we may combine the two groups into one) 
Let  
1X be the values of tumor volume or stage or grade 




   or  )exp()()( 110 xttj    
Where )(0 t is the baseline hazard. 
 
In this section, we consider all patients as a single cohort and performed the analysis again. 
(Subscript c signifying the analysis of the various parameters with regards to all patients 
considered as a single cohort) 
  
2.A) Overall Survival: 
a). Tumor Volume (TVc) – 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 Lower Upper 
TVc -.006 .020 .089 1 .765 .994 .955 1.034 
 
To observe the association of tumor volume on overall survival, we can look at the relative risk, 
exp(B), in the above output. The risk is estimated to be 0.994 times when the tumor volume 
increase by 1 unit based on the sample (a 95% C.I. is 0.955 ~ 1.034). However, the association 
on tumor volume and overall survival is not significant (p-value = 0.765) 
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b). Stage (Sc) – 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 Lower Upper 
Sc .311 .263 1.397 1 .237 1.364 .815 2.284 
 
To observe the association of stage on overall survival, we can look at the relative risk, exp(B), 
in the above output. The risk is estimated to be 1.364 times when advance to next stage based on 
the sample (a 95% C.I. is 0.815 ~ 2.284). However, the association on stage and overall survival 
is not significant (p-value = 0.237) 
c). Grade (Gc)– 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 Lower Upper 
Gc .114 .508 .051 1 .822 1.121 .414 3.037 
 
To observe the association of grade on overall survival, we can look at the relative risk, exp(B), 
in the above output. The risk is estimated to be 1.121 times when advance to next grade based on 
the sample (a 95% C.I. is 0.414 ~ 3.037). However, the association on grade and overall survival 







2.B) Disease Free Interval: 
a). Tumor Volume(TVc) – 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 Lower Upper 
TVc -.006 .013 .209 1 .648 .994 .968 1.020 
 
To observe the association of tumor volume on disease free interval, we can look at the relative 
risk, exp(B), in the above output. The risk is estimated to be 0.994 times when the tumor volume 
increase by 1 unit based on the sample (a 95% C.I. is 0.968 ~ 1.020). However, the association 
on tumor volume and disease free interval is not significant (p-value = 0.648) 
b). Stage (Sc) – 
Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 Lower Upper 
Sc .190 .167 1.294 1 .255 1.209 .872 1.676 
 
To observe the association of stage on disease free interval, we can look at the relative risk, 
exp(B), in the above output. The risk is estimated to be 1.209 times when advance to next stage 
based on the sample (a 95% C.I. is 0.872 ~ 1.676). However, the association on stage and disease 







Variables in the Equation 
 
B SE Wald df Sig. Exp(B) 
95.0% CI for Exp(B) 
 Lower Upper 
grade .401 .328 1.496 1 .221 1.493 .786 2.838 
 
To observe the association of grade on disease free interval, we can look at the relative risk, 
exp(B), in the above output. The risk is estimated to be 1.493 times when advance to next grade 
based on the sample (a 95% C.I. is 0.786 ~ 2,838). However, the association on grade and 





In the second part of the supplementary analysis, we compared the HEV parameters in the 2 
groups as well as the HEV parameters to the tumor characteristics i.e. tumor stage and its grade. 
Tumor volume is excluded as there are it is a continuous variable. 
 
3 A. Control vs. Case – differences on average HEV and 3 ratios: 
A non-parametric test, Wilcoxon-rank-sum test, was performed to test the difference on HEV as 
well as 3 ratios between control and case. 
 Control Case 
Mean/s.e. (n = 30) (n = 35) 
Total number of HEVs (A) 40.085 / 1.83 41.305 / 1.59 
Ratio of dilated HEVs to the total number of 
HEVs(B/A) 
0.149 / 0.0086 0.166 / 0.0186 
Ratio of dilated HEVs with rbcs within its lumen 
with respect to total no. HEVs (C/A) 
0.098 / 0.0078 0.101 / 0.0135 
Ratio of dilated HEVs with rbcs within its lumen 
to total no. of dilated HEVs(C/B)* 
0.646 / 0.0301 
(p=0.0318) 
0.582 / 0.0275 
  * p-value is less than 0.05 
 
The average C/B („Ratio of dilated HEVs with rbcs within its lumen to total no. of dilated 
HEVs‟) in control groups is statistically significantly higher than that in case group (p-value = 
0.0318) 
 
3 B. Stages – differences on average HEV and 3 ratios by case/control groups 
A non parametric test, Kruskal-Wallis test, was performed to test the difference on the A (total 







  Stage  
Mean/s.e. 1 and 2  
(n = 2) 
    3 (n = 12) 4 (n = 16) 
Total number of HEVs (A) 48.625/6.205 44.518/1.98 35.693/2.603 
Ratio of dilated HEVs to the total number of HEVs(B/A) 0.127/0.0095 0.148/0.018 0.153/0.0093 
Ratio of dilated HEVs with rbcs within its lumen with respect to 
total no. HEVs (C/A) 
0.090/0.0074 0.102/0.0147 0.097/0.0099 
Ratio of dilated HEVs with rbcs within its lumen to total no. of 
dilated HEVs(C/B) 
0.706/0.006 0.672/0.042 0.619/0.047 
 Note: Only 1 patient in stage 1 and 1 patient in stage 2 
   
 No significant difference has been detected among stages. 
 
2) Cases: 
  Stage  
Mean/s.e. 0 and 1  
(n = 18) 
2 (n = 13) 3 (n = 4) 
Total number of HEVs (A) 41.949/2.379 42.606/2.395 34.175/3.524 
Ratio of dilated HEVs to the total number of HEVs(B/A) 0.159/0.0146 0.140/0.0133 0.277/0.1475 
Ratio of dilated HEVs with rbcs within its lumen with respect to 
total no. HEVs (C/A) 
0.101/0.0129 0.076/0.0095 0.183/0.0986 
Ratio of dilated HEVs with rbcs within its lumen to total no. of 
dilated HEVs(C/B) 
0.601/0.0339 0.533/0.0548 0.655/0.0398 
 Note: Only 1 patient in stage 0 
 
 No significant difference has been detected among stages. 
 
3 C. Grades – differences on average HEV and 3 ratios by case/control groups 
A non-parametric test, Kruskal-Wallis test, was performed to test the difference on the A (total 
no. of HEV) as well as the 3 ratios among different stages in Control Group; A non-parametric 
test, Wilcoxon-rank-sum test, was performed to test the difference on the A (total no. of HEV) as 







  Grade  
Mean/s.e. 1 (n = 6) 2 (n = 19) 3 (n = 5) 
Total number of HEVs (A) 40.575/4.374 40.339/2.059 38.534/6.606 
Ratio of dilated HEVs to the total number of HEVs(B/A) 0.1482/0.0265 0.1475/0.011 0.1575/0.0101 
Ratio of dilated HEVs with rbcs within its lumen with 
respect to total no. HEVs (C/A) 
0.0961/0.0181 0.0962/0.0109 0.1088/0.0082 
Ratio of dilated HEVs with rbcs within its lumen to total no. 
of dilated HEVs(C/B) 
0.6339/0.058 0.6353/0.0421 0.6995/0.0571 
   




Mean/s.e. 1 (n = 14) 2 and 3 (n = 
21) 
Total number of HEVs (A) 42.54/2.652 40.48/2.007 
Ratio of dilated HEVs to the total number of HEVs(B/A) 0.1598/0.0181 0.1694/0.0289 
Ratio of dilated HEVs with rbcs within its lumen with respect to total no. 
HEVs (C/A) 
0.0985/0.0152 0.1023/0.0204 
Ratio of dilated HEVs with rbcs within its lumen to total no. of dilated 
HEVs(C/B) 
0.5667/0.0487 0.5921/0.0331 
  Note: Only 1 patient in grade 3 
 







In conclusion, our study demonstrates morphologic and functional alterations of the HEVs to 
become the main blood flow carrier in the lymph node. The analysis reveals the relationship of 
high endothelial venules and their metamorphosis in pre-metastatic and metastatic environment 
in regional lymph nodes of tongue cancer patients in correlation with clinical outcomes. Our 
findings coupled with studies elucidating the basis of lymphangiogesis and angiogenesis within 
sentinel lymph nodes support our hypothesis that HEV play a pivotal role and may be the elusive 
junction providing the lymph flow shortcut route into the circulation in sentinel lymph nodes. 
The confirmation of this shortcut and the exploration of the related molecular mechanism of 
establishing the shortcut will broaden our knowledge about lymph circulation in cancerous 





Squamous cell carcinoma of the tongue is one of the most prevalent tumors of the head and neck 
region, epidemiologically it is also one of the cancers with fast rising rate today affecting 
especially the young. The prognosis is worse compared to other equivalent carcinomas of the 
head and neck region as it is one of the cancers with the highest propensity for lymph node 
metastases. Surgery is the mainstay of treatment to achieve cure for this deadly disease and there 
are two equally important aspects to the surgical therapy. The adequate resection of the tongue 
lesion with clear microscopic margins and secondly but more crucially for prognosis ,the surgical 
clearance of its draining lymphatic basin , in the case of tongue carcinoma, these are the cervical 
lymph nodes, classified according to anatomical levels 1 to 7.(Illustration 1)  Historically, radical 
neck dissection has been the gold standard for treatment of the neck with regards to LN clearance 
in surgical treatment of tongue cancers but due to its associated high morbidity, poor patient‟s 
tolerance and inherent inferior cosmetic results, neck dissection has evolved to less radical 
procedures for smaller tumors e.g. supraomohyoid neck dissection and more recently under 
experimental trials, sentinel lymph node biopsy, following the validating successes of melanoma 
and breast carcinoma. There are several clinical and pathological factors proposed as prognostic 
in oral squamous cell carcinoma (SCC), such as stage of primary tumour, site, extension, 
thickness, grade of histological differentiation and perineural invasion. Of all these clinico-
pathological factors, the presence of cervical LN metastasis is the most important factor 
associated with adverse prognosis. Extracapsular spread in LNs has also been recently identified 
as a prognostic indicator as well. (Table 2) Tumor recurrence in the neck after radical neck 




In our series, probably due to our limited and small sample size, we detected a marginal 
statistical significance when we analyzed the overall survival and disease free interval with 
respect the tumor stage, grade and tumor volume (Table 5). However, we consistently detected a 
marginal significance when comparing the 2 groups overall survival based on the presence or 
absence of LN metastasis. (p-value = 0.066). (Figure 4) 
 
It has been proposed and it is currently being validated that SLN biopsy may play the next stage 
in the evolution in the neck management and treatment of tongue SCC (32) . Exploration and 
understanding of this concept coupled with new advances and optimistic results in anti-
angiogenesis therapy involving VEGF anti-metabolites translates the next logical exploration to 
be invested in the study of the pathogenesis of lymph node metastasis. It was shown recently that 
the lumens of the lymphatic sinuses and blood vessels were dilated in SLN before metastasis. 
This has been demonstrated lately in xenograft models but cancer physicians and surgeons knew 
of this fact decades ago, it is called reactive lymphadenopathy, analogous to a reactive lymph 
node during upper respiratory tract infection. We have demonstrated that lymph nodes are 
transformed by the primary tongue tumor to become a functional blood vessel–enriched organ 
before and independent of metastasis, with the changes in the morphology of the HEV to become 
main blood flow carrier in the lymph node. (Figure 6- high power field photo of dilated HEVs 
with rbcs inside) This process of vascularization in the LN (i.e. the HEV morphological 
alterations) appears similar and consistent in human tissues and previous animal models (5) . 
This study presents functional and structural data that the primary tumor is manipulating lymph 
nodes‟ microenvironment and biology to improve the acceptance and proliferation of subsequent 
tumor deposits leading to established metastases.   
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In previous studies, the degree of lymphatic dilation in the SLN was significantly correlated with 
the primary tumor weight, this observation suggests that the lymphatic fluid from the primary 
tumor induced the persistent alteration of the lymph channel in SLN. These results are consistent 
with a recent finding that, in contrast to angiogenesis, in which blood flow proceeds only after 
the vessel develops, lymphangiogenesis can be induced by interstitial fluid channeling (65)  . As 
mentioned, in this aspect this is analogous to immunology studies showing the alteration of 
lymph channels in SLNs can also occur during an inflammatory reaction, which facilitates the 
migration of inflammatory cells (66) The difference in cancer metastasis biology and 
inflammatory process starts here. In endotoxin induced experiments and studies, the dilated 
lymphatic sinuses and vessels in the associated reactive LNs were full of lymphocytes, but in 
contrast in tumor-reactive lymphadenopathy, lymphatics contained minimum or no cellular 
material, suggesting different roles of the SLN lymphatic channels in different pathologic 
processes. It has been well characterized that the HEVs of lymph nodes play an important role in 
recruiting lymphocytes for the generation of immune responses. By expressing homing receptors 
on their surface, which blood lymphocytes can recognize as they pass in circulation, HEV 
provide a unique location where naive lymphocytes can enter the lymph node (67) .  
 
In a previous study (5), we found that the role of HEV was transformed from a lymphocyte 
recruiter to become the main blood flow carrier in the SLN prior metastasis. We have shown and 
verified in this study that in the regional cervical LN, not only could the individual HEV 
morphology change dramatically to carry more blood flow, but the proliferation rate of HEV 
endothelial cells was also increased before metastasis. This transformation of HEV as a 
lymphocytic carrier in LNs to a blood-flow carrier can be seen in large quantity of red blood 
cells visible in the HEV even in both pre-metastatic regional LNS and more significantly this 
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phenomenon is also proven to be more pronounced in the regional LNs of the patients with 
established LN metastasis. We have shown this in our supplementary data that patients with 
lymph node metastases have more dilated HEVS with rbcs in their LNs as compared to patients 
without LN metastasis. The average Ratio of dilated HEVs with rbcs within its lumen to total no. 
of dilated HEVs(C/B) in the control (pN+) group is statistically significantly higher than that in 
case group (p-value = 0.0318).  
 
In addition, with the benefit of patients‟ pathological and follow-up information, we have 
demonstrated statistically that even with an increase of 1 HEV in a high-power-field (HPF), 
regardless of the group, the risk is 1.024 times worse in terms of overall survival. This is also 
consistent with clinical knowledge and natural history of the disease. We know for a fact that 
patients without LN metastases in their regional LNs (i.e. designated as CASES in this study) 
have a significantly better prognosis; this fact is also reflected in our analysis. (Figure 4 showing 
the Kaplan Meier curve of OS for cases vs. controls)  Cases have a 0.428 times the risk of 
Controls with regards to overall survival if they have the same number of HEV.  It is crucial to 
realize that this risk is exponential in nature, so to illustrate the significance of this result, we use 
the following example:   Tongue cancer patient A has proven LN metastases in his cervical LN, 
on further immunohistochemical staining, has zero HEV in a random high-power-field; assuming 
that  everything else (i.e. tumor size, grade, stage, presence of LN metastases etc.) being equal, 
patient B has 100 HEV in a HPF, pt B will have a [ (1.024)
100
 = 10.715 ] more than 10 times 
worse prognosis in terms of overall survival as compared to patient  A. Tongue cancer patient C 
has no LN metastasis and if the HEV amount in a HPF is the same as either patient A or B, 
patient C‟s risk as compared to either patient A or B will be 2.34 times (1/0.428= 2.34) better in 
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terms of overall survival.  Although this did not reach statistical significance (p=0.471), we 
believe this to be a factor of a small sample size as we continue to demonstrate why this appears 
to be the case. 
 
 Assuming that our hypothesis is true, HEV transformation from a normal immunological 
mediator to a tumor metastasis mediator is reflected by morphological changes from a normal 
appearing HEV to a dilated HEV to lastly a dilated HEV containing rbcs. We believe that this 
metamorphosis is a spectrum and this process begins with the HEV increasing in absolute 
numbers, then each of them becoming more dilated and lastly every one of them will become a 
function vessel carrying blood. (Figure 7, 9)  This is the reason why we analyzed our data 
looking at the 3 different stages of HEV transformation (see Material and Methods Section) and 
the ratio comparing each parameter in an attempt to demonstrate this spectrum. (Illustration 3. 
Venn diagram illustrating the relationship between the different HEV parameters (A, B, C). 
 
In our study, we found that this spectrum of metamorphosis is consistent and verified with the 
patients‟ overall survival regardless of their LN metastasis status. We recall that that in the last 
example we illustrated that a patient ‟s OS risk is 1.024 times worse than an equivalent patient if 
there is 1 more HEV in a HPF of his regional LN, the risk is increased to 1.071 if the HEV is a 
dilated HEV. The risk is even higher at 1.116 times if the HEV is a dilated HEV containing rbcs.  
This trend is also reflected if we considered all the patients as one cohort (i.e.  regardless of LN 
metastasis status), a patient‟s OS risk is worsen by 1.004 times  if there increase of 1 dilated 
HEV a in HPF, if that dilated HEV contains rbcs this OS risk in increased to 1.008 times (see 




In the treatment of tongue carcinomas or in any head and neck cancers, disease free interval is as 
important as it signifies the failure of loco-regional control of which there is little effective 
therapy. Further surgery e.g. neck dissection to remove loco-regional recurrences is plagued with 
high morbidity and mortality and this coupled with poor chemotherapy and radiotherapy 
response rates in recurrences, this more often than not equates to an unfortunate rapid demise of 
the patient‟s condition. Disease free Interval (DFI) is also analyzed in the same manner to the 
three different HEV morphological phenotypes. Normal HEV, Dilated HEV, Dilated HEV with 
rbcs within its lumens (A, B, C respectively as defined in the Section Patients, Material and 
Methods). 
 
We found statistical significance in the relationship between the total number of HEV (A) and 
DFI when we controlled for the group (i.e. taking in the presence of LN metastasis as a factor). 
(p=0.022). This significance is preserved when we analyzed all the patients as a cohort 
(p=0.023). In another words, this translates to mean that the quantity of HEV is inversely related 
to DFI whether you consider the patient‟s LN status or choose to disregard it as a factor. If you 
consider the LN status and take it into statistical consideration, if there is one more HEV in a 
HPF, the DFI is 1.051 times worse than zero HEV. It is again important to note that the 
relationship of the quantity of HEV with respect to DFI is exponential in nature. For example, a 
patient with 100 more HEV (A) in a HPF has {(1.051)
100
 =144.63} 144 times shorter DFI as 
compared to a equivalent patient with one HEV. Excluding the group effect and consider all the 
patients as a cohort, in a patient with 1 more HEV in a HPF, the DFI is also about 1.051 times 




We then analyzed out results further. We looked at the different ratios of abnormal HEV and 
compared them to several clinic-pathologic parameters namely overall survival, disease–free 
interval, tumor volume, stage and grade of the tumor. The details results are specified in the  
results supplementary section. 
 
There is a general trend observed. The more advanced the disease is, the higher the 
ratio/percentage of abnormality of HEV. This can be seen in when we analyzed OS and the 2 
ratios.  The OS relative risk worsens by 1.078 if the ratio B/A (ratio of dilated HEVs to the total 
number of HEV) increased by 1, the OS relative risk worsens by 3.624 times if we consider the 
ratio of dilated HEVs with rbcs to the total number of HEVs increased by 1. Most importantly, if 
we consider the most abnormal form of HEV (dilated HEV with rbcs within its lumen, C) and 
looked at it as a ratio to the total no. of HEV, a patient‟s OS relative risk worsens by 17.884 
times if this ratio (C/A) increase by a factor of 1.  This observation approaches marginal 
significance. (p-value = 0.171). (Figure 8) 
 
 
In this study, we have shown the relationship of HEV and their transformation in a cancerous 
environment. We also note that in previous studies the HEV morphology did not alter at all in 
endotoxin-induced lymphadenopathy, implying a selective reaction of HEV in the cancerous 
condition. Distinct, differentiated gene expression has also been reported when the endothelial 
cells respond to the changing of their microenvironment (68) . In a previous study, it was shown 
that the cellular morphology of the tall endothelial cells forming HEVs changed dramatically to 
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become flat endothelial cells in the presence of cancer. As a consequence, the HEV was 
remodeled from a thick-walled, endothelial vessel with a small lumen to a thin walled, large-
lumen vessel (Figure 11 and 14), shifting its function from recruitment of lymphocytes to 
becoming a blood vessel. These facts indicate that the blood vessel endothelium has tremendous 
potential to adapt its environment. The confined lymph and blood channel alterations within the 
SLN but not in the next station lymph node imply that an inducer from the primary tumor is 
functioning locally with the existence of an active primary cancer. VEGF-A has been found to be 
an inducer of lymphangiogenesis in SLNs (49) . Other studies shown that serum level of VEGF-
A was elevated in patients with late-stage NPC (69). VEGF-A is a secreted protein factor that can 
travel in blood to other lymph nodes, these findings suggest that there may be other inducers 
involved.   It is also of interest to explore the role of HEVs after the establishment of a metastatic 
tumor nest. The enlarged, remodeled HEVs could integrate into the metastatic tumor vasculature 
with further differentiation, characterized by the gradual loss of their specific marker MECA-79 
from the tumor margin to the central part of the metastatic tumor nest. It has been explained that, 
compared with primary tumors, the more rapid growth of metastatic lesions in the cervical lymph 
nodes of NPC patients was due to clonal selection of the cancer cells during metastases, with 
highly proliferative clones disseminated to the cervical nodes. However, based on our findings, 
the metastatic tumor vasculature in lymph nodes consists of many large blood vessels derived 
from normal HEVs, suggesting that the efficiency of nutrition and oxygen supplies could be 
better for the metastatic tumor cells in the involved lymph node. The enrichment of the blood 
supply in the lymph node before and after metastasis may favor the growth of newly arriving 
metastatic cancer cells. Consequently as known in clinical situations seen in the long term 
follow-up of cancer patients,  the involved regional lymph nodes may become manifest, whereas 
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the primary tumors remain clinically occult for years (70) . Moreover, the high density of 
functioning blood vessels in lymph nodes may subsequently facilitate the metastasis of cancer 
cell to distant organs. High endothelial venules being further integrated into the established 
tumor nests in the LN is a good example of vessel co-option, which is an established and 
important cancer vasculature development (48). It will be important to elucidate if the highly 
vascularized premetastatic SLN is associated with an increased metastatic potential. Control of 






14. Future Directions 
If this hypothesis is true about HEV role in cancer metastasis, we can block this remodeling 
process and see if it prevents distant metastasis. This will confirm the HEV‟s central role in the 
pathogenesis of metastasis. 
 
Further studies need to concentrate on the pathways of HEV transformation. A master control 
gene for the growth and differentiation of HEVs remains to be identified. With regards to this, a 
recently identified nuclear factor, NF-HEV has potential and is interesting, because it is 
preferentially expressed by HEVs (71) .  Identification and characterization the molecular 
pathways and the control genes would have considerable clinical applications. It would enable 
the design of study protocols to induce the formation of HEVs in various tissues, including 
tumours, improving vaccination strategies against pathogens and cancers. Therefore, there is a 
wealth of translational applications with regards to targeting HEVs as a ligand for cancer 
investigational therapeutics. It paves the journey in the discovery of many unknown genes and 








Our study did find some preliminary associations in HEVs with regards disease pathology and 
clinical correlations; however, it is premature unequivocal conclusions. Our study has its 
limitations and there are mainly associated with 2 major factors. It is a retrospective study with a 
limited sample size and its lacks a molecular experimental component. 
 
 Since it is an exploratory observational study considering that HEVs role in cancer and 
metastasis is still in its preliminary phases of full comprehension. The limited sample size of 65 
patients (Controls n=28; Cases n= 37) is derived from a 5 year long experience and it is a subset 
of a large group selected from the Head and Neck database in a large tertiary institution with the 
oldest and largest surgical department in country (Department of General Surgery, Singapore 
General Hospital). This sample population size was deemed to be sufficient to show a significant 
difference in their overall survival between 2 the study groups.  Nonetheless, due to the efforts to 
reduce confounders and to minimize errors and difficulty in the interpretation of our results, a 
strict selection criteria was applied to have a homogenous group. We thus included only tongue 
cancer patients are that treated surgically with a component of the corresponding lymphatic 
system and drainage basin resected and its status proven pathologically with a good documented 
follow-up period of at least 2 years.  Due to the limitations of a small sample size, we believe 
that some of the associations in our hypothesis did not reach statistical significance due to this 
fact. The retrospective nature of the study is no doubt a limitation but as the nature of this study 
does not involve therapeutics or a comparison of 2 factors, the retrospective nature actually 
works to our advantage. We are able to collate a large sample study size with confirmatory 
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clinic-pathological data within a short period of time and concentrate our time and effort in the 
investigative and analytical aspects. 
 
Secondly, one main investigative feature of our study concentrated largely on the 
histopathological assessment of the patients‟ lymph node status preserved tissue paraffin blocks 
in storage. There are limitations to using tissue paraffin sections and the techniques available are 
limited to date. There are deficiencies in the consistency of the quality of the tissue paraffin 
blocks, some tissue blocks are less well preserved than others, especially the older blocks may 
not be stored in optimal conditions over time. We use a self-experimented optimized technique 
for our immunohistochemistry using anti-MECA-79(also named peripheral node addressin, 
PNAd) antibody) as our sole antibody for HEV. Ideally we would like to use at least 2 different 
HEV markers to confirm our findings in event of specificity and sensitivity inaccuracies in the 
antibody to HEV, however, there is no other commercially available antibody for HEV to date 
and we do not have the facility and resources to generate a new and more specific antibody for 
HEV. One assumption in the study is that MECA-79‟s specificity and sensitivity is high enough 
and representative of all HEVs in our tissues. Ultimately,  we need analysis at the level of 
molecular genetics will prove to be the critical factor in confirming the value of 
immunohistochemical stains in the assessment of biological behavior and prognosis. A 
considerable problem to be overcome is the marked variation in tissue staining that can be 
encountered, both in different, patients, neoplasms and in different laboratories. These 
differences reflect the varied biology of neoplasms, as well as differences in fixation and 





A major limitation in the study is the lack of experimental evidence and results to strengthen our 
observatory data. The next step in confirming our conclusion is to have molecular pathway 
experiments and studies to elucidate the pathways and the molecular mechanisms underlying the 
phases of HEVs‟ metamorphosis peri-metastasis. In order to systematically study the role of the 
modified HEVs as a blood vessel and a shortcut mechanism for metastasis, our IHC and clinic-
pathological correlations are not adequate, we require appropriate tracer molecules with real time 
imaging technology and xenograft experiments studying the mechanism of the lymph node 
microenvironment changes correlating to the spreading of cancer cells. As the objective of this 
study is to establish the presence of a correlation between HEVs and clinico-pathological 
features in cancer patients, the molecular experiments are not included but are planned for as 
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